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5Abstract
Increasing numbers of drugs are being developed for the treatment of multiple
sclerosis. Measuring outcomes is key to assessing the efficacy of drugs in clinical trials
and monitoring response to disease-modifying drugs in individual patients treated
upon registration. In both clinical trials and the clinical setting, most outcomes reflect
relevant aspects of the disease, from clinical or neuroimaging perspectives, such as
the presence of clinical relapses and accrual of disability, or the presence of visible
inflammation and brain tissue loss, respectively. However, most of the measures
employed in clinical trials to assess treatment effects on these relevant outcomes (i.e.
outcome measures) are not used in routine practice. In the trial setting, the choice of
outcome measures is crucial because they determine whether a drug is considered
effective and can move to the next step of development; in the clinic, such outcome
measures may be used for individual decision-making, such as choosing a first-line
disease-modifying drug or escalating to a second-line treatment. This review discusses
the clinical, neuroimaging, and combined outcome measures, including patient-
reported ones, that are used in both trials and the clinical setting, to help clinicians
and researchers to navigate through the multiple options when choosing an outcome
measure. The barriers and limitations that need to be overcome to translate outcome
measures from trials to a clinical setting are also discussed.
Introduction
6Multiple sclerosis (MS) is a major cause of irreversible disability in young adults.
Neurological disability in MS may occur as a consequence of acute relapses with
incomplete recovery, or as a result of a clinical progression that occurs independently
of the presence of relapses1. The pathological processes that lead to the development
of acute disability are different from those that contribute to clinical progression.
Acute inflammatory demyelination is responsible for the development of relapses,
whilst neurodegeneration is the main determinant of progressive disability2. There are
no few licensed treatments to slow progressiveion in MS, whilst numerous disease-
modifying treatments (DMT), which reduce the frequency of relapses in relapsing-
remitting (RR) MS, are available. Current efforts are shifting towards progressive MS3,
and the number of trials has increased steadily over the last five years.
Measuring appropriate outcomes is central to assessing the efficacy of novel drugs,
determining whether a drug can be moved to the next step of a drug development
programme, and its regulatory approval. The efficacy of an experimental therapy
cannot be demonstrated if the selected measure is unable to capture it, and no trial
designs can compensate for inappropriate and poor measures. Outcome measures in
RRMS trials focus on clinical (relapse) and radiological (lesion count) disease markers
of inflammation, whilst in progressive MS the emphasis is on measures of clinical
progression and (brain) atrophy as markers of neurodegeneration. Ideally DMTs
would prevent both inflammation and neurodegeneration4.
In the clinical setting, similar measures are used to monitor the response to DMTs in
the individual patient, and, consequently, for decision-making, such as choosing a
7specific initial DMT or escalating to second-line treatment. Although Mmost of the
outcome measures used in clinical trials are not used in routine practice, the level of
standardization and the quality control are lower in the clinic than in trials, because of
technical, financial and logistic barriers. However, important efforts have been made
to standardise outcome measures in the clinic, especially in relation to monitoring
treatment efficacy, in order to allow comparisons across centres5,6.
The answer to the question what makes an outcome measure appropriate is a
complex one. The psychometric properties of the measure must be appropriate for
the study, and the chosen measure should be reliable and valid. Reliability indicates
that the data collected are accurate and reproducible, while validity refers to the
ability of the tool to measure what it is supposed to measure. In addition, the outcome
measure must be responsive, i.e., detect changes in the specific functions and areas
that are expected to occur as a consequence of the intervention/therapy7. The degree
of the predicted changes in the outcome measure and the period over which they are
expected to happen are also factors that need to be considered8. Well-known,
traditional endpoints used in MS trials have the advantage that are immediately
understood by clinicians, whereas novel outcomes may provide insights into more
subtle, but relevant, treatment effects that would have been overlooked when using
traditional endpoints. In the clinical setting, the choice of a response measure needs
to consider whether the administration of the tool is easy, the data collected are
clinically useful, and the interpretation of the test results is straightforward.
8This review discusses the clinical and imaging outcomes used in clinical trials, stressing
their advantages and limitations, which need to be considered when interpreting the
results of clinical trials or designing new studies, with a particular focus on combined
outcomes, as recently employed in progressive MS trials. The response measures used
in routine clinical practice are also reviewed, and attention is given to their value and
practicality. Clinically meaningful outcomes from the perspectives of patients and
healthcare professionals are also discussed, with a view on their complementary role
to more classical (objective) outcomes to detect treatment effects.
Outcomes in clinical trials
In this section, we first describe the clinical, neuroimaging and the other outcome
measures that have been used in clinical trials, especially in phase III trials, and then
the combined clinical and MRI measures.
Clinical outcomes
We have divided the clinical outcomes used in clinical trials into: clinical relapses,
measures of disability progression, and patient reported outcome measures (PROMs).
Relapse-based outcomes are prevailing in trials with RRMS patients, whereas
progression-related outcomes are prominent in progressive MS trials. PROMs can be
observed in all types of trials. , but may be particularly relevant in trials with
progressive MS patients, who are more likely to present with symptoms such as
fatigue, pain or depression, than RRMS9.10Regulatory agencies have therefore shown
9a growing interest in the use of PROMs for trials in MS over recent years9,10, to
measure common and disabling symptoms such as pain, fatigue and depression.
Clinical relapses
The majority of phase III trials have been carried out in patients with RRMS, and, to a
lesser extent, with the clinically isolated syndrome (CIS) (Figure 1). Since these trials
aim to reduce (or suppress) the inflammatory activity responsible of acute relapses,
their main outcome measure is relapse counting (Tables 1 and Supplementary Tables
1 and 2).
These relapse-centred outcome measures can be classified into four groups
(Supplementary Tables 1 and 2): (i) quantification of the number of relapses in a
discrete fashion (which are the most widely used) (ii) those that quantify the number
of relapses as a binary phenomenon, such as the proportion of patients without
relapses (relapse-free population) –or its opposite - the proportion of patients with at
least one relapse (non-relapse-free population)–, (iii) metrics that quantify the time
to the first relapse while on treatment (which are common in trials in CIS patients),
and (iv) composite outcome measures.
An additional group that could be considered is based on the severity of the relapses,
such as those associated with hospital admissions and intravenous steroids.
A relapse is generally defined as new or recurrent neurological abnormalities that are
separated by at least 30 days from the onset of the preceding event. It lasts at least
10
24h, and occurs without fever or infection11. The definition of a relapse has changed
over time and has become more stringent in recent trials compared with early
trials12,13. For example, in the phase III ALLEGRO trial, which compared laquinimod
with placebo in RRMS, neurological symptoms had to last at least 48h to be considered
relapses13. The vast majority of Some trials demand an objective assessment by the
examining neurologist16, and request a specific increase in the Expanded Disability
Status Scale (EDSS) score and associated Functional System sub-scores14-16.
The most widely used outcome measure is the annualised relapse rate (ARR: number
of relapses during the treatment period per patient-year), which belongs to the first
abovementioned group (i) above and has been used so far in more than 40 phase III
trials, most of which are in RRMS (Table 1 and Supplementary Table 1). In more than
half of these trials, and in all trials with RRMS, the ARR has been used as the primary
trial endpoint (Table 1). The ARR is easy to understand and compute, and it is thought
to reflect well the extent of inflammatory activity of the disease. However, it may lack
specificity in respect to MS course severity, since the background level of disability
and the severity of the attack are not captured. This limitation has prompted the
development of the annualised rate of severe relapses, which are those relapses that
require intravenous steroid treatment and/or hospitalisation13, or those that entail a
high-level of disability17, which has been used since 1993 as a secondary endpoint
(Table 1). However, the lack of standard guidelines to treat MS relapses implies there
is an enormous inter-site variability in terms of management of relapses and it might
not be appropriate to consider these measures as potentially eligible clinical outcomes
in trials.
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The second group of relapse-centred outcome measures includes the relapse-derived
binary outcome measures, which have been used since the very beginning of the trials
in MS, but have become more popular over recent years with the testing of highly
effective drugs that may lead to a relapse-free status. The percentage of relapse-free
patients and the percentage of patients with at least one relapse may depend on the
length of the study, as the risk of getting a relapse may increase with time; therefore,
the design of the study needs to be considered when comparing these outcome
measures among trials. For example, the GATE study, a 9-month placebo-controlled
phase III trial, where generic glatiramer acetate (GA) was compared to brand GA and
placebo in RRMS patients, the percentage of relapse-free patients in the placebo
group was 79.3%. Instead, in RRMS trials with longer durations, usually 24 months,
such as the FREEDOMS14 or the ALLEGRO13 studies, that percentage is around 50-60%.
This has immediate consequences from a statistical point of view: to be able to detect
a given difference in relapse-free patients between placebo and active arms, we will
need much greater sample sizes if the percentages in both groups are around 50%
than if they are closer to 0% or 100%.
The most relevant measure within the third group is time-to-relapse, often used in CIS
studies, where the occurrence of the first relapse since study entry indicates
conversion to clinically definite MS (CDMS)18-20; therefore, time to CDMS is often the
primary trial endpoint (Table 1 and Supplementary Table 1). Since the development
of a new lesion on MRI in patients with CIS can also confirm a diagnosis of MS
(assuming that the dissemination in space criteria are also fulfilled), according to the
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2001 McDonald criteria20, time to McDonald MS has also been used as trial endpoint
in CIS trials, although this measure requires a trial design with repeated MRI scans and
is heavily dependent on frequency of MRI assessments. At present, a few phase III
trials have used time to McDonald MS as trial endpoint: the BENEFIT study21, which
compared interferon beta-1b 250µg SC every other day versus placebo, the REFLEX
study22, comparing three-weekly and weekly INTERFERON beta-1a versus placebo,
and the TOPIC study23, comparing oral teriflunomide 7mg and 14mg versus placebo
(Table 1). In the both BENEFIT and REFLEX studies, where time to McDonald MS was
the primary outcome, this reached statistical significance well before time to first
relapse and allowed for a dose differentiation in REFLEX that was not apparent using
clinical outcomes22.
The most important outcome within the fourth group is “time to treatment failure”,
which is a primary composite endpoint, recently introduced in the TENERE study,
which compared oral teriflunomide 7mg and 14mg versus interferon beta-1a in
RRMS15. The time to treatment failure is defined as the occurrence of the first
confirmed relapse while on treatment, or permanent treatment discontinuation for
any cause15 (Table 1); this outcome is thought to account for all the factors that
determine the effectiveness of a therapy, such as efficacy, safety and tolerability, and,
therefore, may be applicable to the real-life clinical setting.
Measures of disability progression
Measures of disability progression are generally used as primary outcome measures
in phase III trials in progressive MS (Table 1 and Supplementary Table 3). Most pPhase
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III trials in progressive MS using these outcome measures have reported negative
results24,25, with the exception of the ORATORIO study, which compared IV
ocrelizumab versus placebo in primary progressive (PP) MS26 and the EXPAND trial,
which compared oral siponimod to placebo in secondary progressive (SP) MS27. Many
trials in RRMS (and CIS) patients have also included disability progression as a trial
endpoint (Table 1 and Supplementary Tables 1 and 2), either secondary or primary,
suggesting that targeting clinical progression is also a may be a priority even in the
relapsing forms of MS.
Similarly to the relapse-centred outcomes, dDisability progression-related outcomes
can be classified into four five groups: (i) those that quantify the amount of
progression in a continuous fashion, such as changes in the Expanded Disability Status
Scale (EDSS)28 scores, or the EDSS score at follow-up, (ii) metrics that quantify the
amount of progression as a binary phenomenon, such as the proportion of patients
with (or without) (confirmed) disability progression, (iii) quantification of the
(confirmed) improvement in disability progression also binary, (ivii) metrics those that
quantify the time to confirmed disability progression (CDP), and (iv) composite
outcome measures (see Table 1).
The most frequently used outcome measure in the first group is the absolute change
in the EDSS score from baseline to follow-up (Table 1 and Supplementary Table 3). Of
note, in some trials, such as the PRISMS17 and CARE-MS I29 and II30 trials, changes in
the EDSS raw scores are reported, but in other trials, such as the Copolymer-1 trial in
RRMS31, the EDSS-step methodology, instead of raw EDSS changes, is used. It consists
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of assigning new values to observed EDSS changes depending on the position of the
initial EDSS score in the whole scale. This approach was meant to overcome the non-
linear behaviour of the EDSS. The main limitations of the EDSS-based measures are
that a worsening in EDSS does not reflect which functional system changes and that a
relapse-associated transient deficit may lead to a (transient) change in the EDSS32.
Additionally, the EDSS may not be sensitive to deterioration of the upper limb motor
function, cognitive function or short-distance walking, which may occur in patients
with progressive MS and high EDSS scores33. Besides, the absolute change in EDSS,
especially when relying on a small number of visits, may be affected by noise due to
the low inter-rater and intra-rater reproducibility of the scale, namely in the lower end
of the scale34. The EDSS score does not reflect the whole patient’s functional
impairment, since it has a low ability to discriminate people with different levels of
disability according to the Barthel Index35, a measure of functional independence in
10 daily activities36. Therefore changes in scores other than EDSS, such as MS
Functional Composite (MSFC)37, and its subtests38,39, Regional Functional System
Score (RFSS), ambulation index, arm index, and cognitive tests40,41, from baseline to
follow-up, have been included into some trials to complement the EDSS (Table 1 and
Supplementary Table 3). Cognitive tests that have been used in phase III trials include
the: Paced Auditory Serial Addition Test (PASAT), which is one the subtests of the
MSFC37; Rao’s Brief Repeatable Battery (Rao’s BRB)42. With the PASAT, the changes in
the z-score over the trial period time was used43,44. For Rao’s BRB, different trials have
used different outcome measures: whereas in the phase III North American trial of SC
interferon beta-1b in SPMS the outcome measure was the change in a composite
neuropsychological score41, in the ARIANNA study (atorvastatin add-on vs. placebo
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add-on in RRMS patients on SC interferon beta-1b treatment), the outcome measure
was the change in the percentage of patients with mild or severe cognitive
impairment, defined as failure in one-two or three or more tests, respectively40.
With regard to the oOutcomes in the second and third and fourth groups , they vary
considerably between studies and are numerous (Table 1 and Supplementary Table
3). Confirmed disability progression (CDP) is defined as a worsening of the EDSS
(usually 1.5-step EDSS progression when starting EDSS is 0, 1-step EDSS progression
for EDSS≤5.5, or 0.5-step EDSS progression for EDSS>5.5) that persists for either three 
or six months. It has been demonstrated that 3-month and 6-month CDP overestimate
the long-term accumulation of irreversible disability by 30% and 26%, respectively45.
Longer disability confirmation periods (12 and 24 months), although not completely
free from such bias (overestimation of 20% and 11% respectively), would be
recommended to detect true, irreversible disability, with a possible little effect on the
sensitivity of the progression criteria45. However, so far, no trials have used such long
periods to confirm disability progression. Most trials have used both 3-month and 6-
month disability progression, although some recent studies, such as CARE-MS I29 and
II30, have used only the 6-month CDP outcome. If a trial uses the time to 3-month CDP
(or the percentage of patients with 3-month CDP) as primary endpoint, then the time
to 6-month CDP is a secondary endpoint.
The MSFC or its subtests, which are the 25-foot Timed Walk Test (TWT), the 9-Hole
Peg Test (9-HPT) (which reflects the motor impairment in the upper limbs), and the
Paced Auditory Serial Addition Test (PASAT) (which reflects the speed of (auditory)
16
information processing and calculation ability)39, can be used instead of the EDSS to
define the CDP. Although the training effects often seen on the PASAT could
theoretically be responsible for a lower responsiveness of the MSFC than the EDSS to
detect disability progression46, this is not supported by the results of the trials
published so far, where MSFC-derived outcomes seem to be more sensitive than those
derived from EDSS. For example, the CARE-MS II30 or the FREEDOMS II47 trials, carried
out in RRMS, or the IMPACT trial, in SPMS43, showed significant results in the MSFC
but not in the EDSS. Instead, trials that showed significant effects in the EDSS, such as
CARE-MS I29 and the FREEDOMS14, tended to show also significant results in the MSFC.
Further attempts have been made to improve the sensitivity of MSFC and its subtests
to disease progression, and therefore increase its sensitivity to treatment effects. For
instance, it was suggested that only increases of at least 20% in MSFC subtests were
clinically meaningful and had an acceptable signal-to-noise ratio, suggesting that
clinical trials should use outcomes based on these subtests as binary metrics48.
However, so far, only one phase III trial, the ARIANNA study, which compared oral
atorvastatin add-on to SC interferon beta-1b in RRMS, has used this 20% cut-off to
define the MSFC-related outcome measure40.
Among the outcome measures of the third group, the most widely used one is the
sustained improvement in the EDSS score, which was used as a secondary outcome in
the CARE-MS II trial30 and The Copolymer 1 Multiple Sclerosis study31 (Table 1). In
phase III trials, it has only been used when drugs were to be tested in patients with
RRMS, possibly reflecting the role of acute inflammation in the development of
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disability in these patients. Quite recently, a phase II study carried out in progressive
MS, the biotin study, also used the improvement of disability as an outcome measure
–in particular, as a primary outcome measure49. In this study, which showed positive
results, the improvement of disability was not only reflected by improvements in the
EDSS score, but also in the TWT score49. Improvement was considered if there was a
decrease in the EDSS of ≥0.5 or ≥1 points, if baseline score was between 6 and 7 or 
between 4.5 and 5.5, respectively, or if there was a decrease in the TWT of at least
20%. Sustained improvement of disability as outcome measure may therefore reflect
clinical changes secondary to not only remission of inflammation but also tissue
regeneration, which may be expected in the new era of drugs being tested in
progressive MS, such as the abovementioned biotin49, simvastatin (tested in the phase
II MS-STAT trial50) or oxcarbazepine (being currently tested in the phase II PROXIMUS
trial51).
Composite endpoints, which are in the fourth group of disability progression
measures, facilitate higher event rates and theoretically increase the sensitivity of the
progression parameters, thereby reducing the length of the trial and the sample size.
Besides, they theoretically reduce the risk of multiplicity and so the risk of type I error9.
However, composite endpoints should be pre-specified before starting the trial and
their individual components should only be tested when there is a statistically
significant treatment effect for the composite, unless the components have been pre-
specified as outcome measures too9. A recent reanalysis of a PPMS trial showed that
composite endpoints including different disability measures allows detection of larger
treatment effects, then reducing the sample size needed for clinical trials52. The
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highest efficiency and event rate estimates were obtained by using a sustained
disability progression endpoint confirmed by any two of the following: [EDSS and TWT]
or [EDSS and 9-HPT] or [TWT and 9-HPT]. This endpoint usefully combines the logical
“and” and “or” criteria, maximizing the likelihood to detect a clinical event. However,
composite endpoints are only valid when the composite includes outcomes that are
causally related to the treatment53.
A recent phase III trial in PPMS used as primary outcome measure the time to 3-month
CDP based on a composite endpoint, defined as the presence of at least one of the
following three changes: increase in EDSS (1 if EDSS<5.5 or 0.5 if EDSS ≥5.5), increase 
in ≥20% in 9-HPT, and increase ≥20% in TWT54. Post-hoc re-analyses of trial data have
suggested that this composite endpoint may separate MS patients with ongoing
progression from those who are stable54, thereby representing an improved endpoint
for disability progression trials. Another composite outcome used as secondary
endpoint in a progressive MS trial55 is the time to a 3-month CDP or to a confirmed
20% worsening in the 9HPT treatment failure (Supplementary Table 3).
Patient-reported outcome measures
Patient-reported outcome measures (PROMs) are self-completed questionnaires that
measure the impact of the disease on daily activities, social functioning and quality of
life. In 2009, the Food and Drug Administration (FDA) published a guidance on
PROMs9, which were defined as ‘any report of the status of a patient’s health
condition that comes directly from the patient, without interpretation of the patient’s
response by a clinician or anyone else’9. In 2016, the European Medicines Agency
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defined PROMs as any data directly reported by a patient that is based on his/her
perception of a disease and its treatment (www.ema.europa.eu), thereby further
developing the concept of “personal perspective”. The term PROM is an umbrella
term, which includes evaluations of health-related quality of life, health status, well-
being, satisfaction with treatment, adherence to treatment, and symptoms.
Therefore, PROMs complement and support the outcome measures based on clinical
assessments, and, as mentioned in the 2009 guidance of the FDA, they can be used in
clinical trials to measure the risks of a given treatment as well as its benefits9,56.
PROMs can be divided into two groups: condition-specific and generic PROMs. In the
first group, there are tools designed for MS, which cannot be extrapolated to the
general population and are sensitive to detect an MS-induced change. Examples of
MS-specific health-related quality of life PROMs are the 29-item MS impact scale
(MSIS-29)57, the patient-reported indices in MS (PRIMUS)58, and the MS quality of life-
5459. Thirteen fatigue-centred PROMs have been proposed in 20 years, and the most
popular are the fatigue severity scale (FSS)60 and the fatigue impact scale (FIS)61 (Table
2). The MS-specific PROMs that measure the impact of motor impairment on daily
activity, such as the Arm Index37 and the Multiple Sclerosis Walking Scale (MSWS-
12)62,63, have been frequently used as trial endpoints over the last 5 years54,64,65 (Table
2). It has been suggested that a reduction of 4-6 points on the MSWS-12 is clinically
meaningful66, although the MSWS-12 has also been used as a continuous measure,
without any thresholding, in a symptomatic trial (i.e. the Fampridine trial)67. Many
generic PROMs, such as those that focus on symptoms, such as pain, tremor, and
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spasticity, have been used in symptomatic trials in MS68,69, but a deep discussion of
these is outside the scope of this review.
PROMs that in future may be further studied and validated for use in clinical trials and
clinical practice are the patient-determined disease step (PDDS), which is a simple and
economical scale compared with the EDSS, but correlates with it and its functional
system scores70, and the subscales of both the MFIS and MSIS-29. A recent trial has
included the physical subscale of the MSIS-29 as a co-primary endpoint of the study
together with time to EDSS-based 6-month CDP65. This indicates that composite
endpoints may be obtained by combining objective scales (e.g., EDSS) and PROMs,
although the same limitations associated with the combined scores discussed above
apply to these combined endpoints.
Neuroimaging outcomes
We have divided the neuroimaging outcomes used in clinical trials into: focal brain
lesions, brain and spinal cord atrophy measures, and novel MR outcomes for
neurodegeneration and remyelination.
Focal brain lesions
MRI measures of focal brain lesions often serves as primary endpoints in phase II trials
and typically secondary outcomes in phase III trials. They are particularly relevant to
trials carried out in patients with RRMS and CIS, which test the efficacy of medications
targeting the inflammatory activity71 (Table 3 and Supplementary Tables 4 and 5),
although they are also used in trials in progressive MS (Table 3 and Supplementary
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Table 6). The most commonly used MRI measures are based on T1 gadolinium
enhancing and new T2 brain lesions, which reflect the occurrence of new
inflammatory activity. In particular, Gadolinium enhancement signifies breakdown of
the blood-brain barrier as a consequence of acute inflammation in the CNS. However,
there is a fundamental difference between T1 gadolinium enhancing and new T2 brain
lesions, since T1 gadolinium enhancing lesions are transient (average duration of 3
weeks72) and a single scan will miss cumulative new inflammation over a period of
time. Instead, given the (generally) non-transient nature of the T2 lesions, ‘new T2
lesions’ with respect to the last scan would capture cumulative new inflammation
between the last and the current scans. Nonetheless, In particular, the ‘number of
gadolinium-enhancing lesions’ during or at the end of follow-up is the most widely
used trial outcome in all phase III trials (Table 3). Gadolinium enhancement signifies
breakdown of the blood-brain barrier as a consequence of acute inflammation in the
CNS. T1-hypointense lesions are visible in both the acute phase of a lesion
development (corresponding to the lesional oedema) and the chronic phase73,74; in
the latter case they are called permanent black holes (PBH), which have been mostly
used as a post-hoc measure of tissue destruction and recovery13.
Lesion-derived measures can be divided into three categories: (i) outcomes that
measure the occurrence of new lesional activity during the trial, such as the number
of new and/or enlarging T2 lesions or new T1 gadolinium enhancing lesions, (ii)
outcomes that quantify the total lesion volume, either T2-hyperintense, T1-
hypointense or gadolinium-enhancing lesion volume, and (iii) those that estimate the
inflammatory activity as a binary phenomenon, such as the proportion of patients
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without gadolinium enhancing lesions. Finally, there would be a set of metrics that
could be included within the first group, since they reflect new, acute lesional activity,
and that are derived from the combination of different MRI measures. An example of
these composite MRI measure is the number of combined unique active (CUA) lesions,
which describes the total number of active lesions in the widest sense and includes all
new, enlarging T2 lesions or new enhancing lesions, provided that the same focal
lesion is counted only once. This endpoint was originally proposed by Paty and Li and
was already used in the first clinical trials in RRMS. In CIS trials, it was used for the first
time in the early 2000 by the ETOMS study75, and in SPMS trials, it was first used in
the SPECTRIMS study76,77. So far, at least 13 phase III trials have used it (Table 3).
The greatest advantage of lesion-related markers is that they provide objective
measures of the underlying pathology and correlate with clinical outcomes in RRMS,
in particular with relapses, at least in the short/medium term78. It has been
demonstrated that more than 80% of the between-trial variability in terms of
treatment effects on relapses is explained by the between-trial variability in terms of
treatment effects on new T2 lesions on MRI79. In addition, treatment effects on
relapses of phase III trials can be predicted by the treatment effects on lesion-related
outcome measures in the corresponding phase II trials that used the same drug80.
Another advantage of lesion-related measures is that, given their high sensitivity, they
allow the comparison of two active drugs, which can be difficult when the outcome is
clinical relapses. For instance, in the GATE study, which compared generic glatiramer
acetate with the originally branded drug, lesion-related outcomes were used to show
equivalence of the two drugs81.
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The counting of new T2 lesions can be limited by factors such as high pre-existing
lesion load, suboptimal repositioning of serial scans and poor inter-observer
reproducibility. Image subtraction has been proposed to overcome these issues, thus
providing good visualization and quantification of both active and shrunken or
resolved T2 lesions82. The combination of automated identification of new/enlarging
lesions with automated lesion subtraction may be useful to improve cost-
effectiveness and reduce the risk of adverse events associated with gadolinium
administration83.
Brain atrophy measures
The rationale behind the use of brain atrophy in clinical trials is that it reflects
neurodegeneration, which is the pathological process most consistently linked to
accrual of disability84-86. Total brain volume/fraction is the non-lesional outcome
measure most commonly used in phase III trials (Table 3). It is generally used as a
secondary outcome measure in phase II and III trials, such as the FREEDOMS study14,
where fingolimod was compared to placebo, or the CARE-MS I29 or II30 studies, where
alemtuzumab was compared to interferon beta-1a. Nonetheless, it has recently been
used for the first time as primary endpoint in phase II50 and phase III trials in secondary
progressive MS (http://www.ms-smart.org, accessed on 29/061/2017; and
https://clinicaltrials.gov/ct2/show/NCT01910259?term=MS+smart&rank=1,
accessed on 29/061/2017), and also in the ongoing phase II ARPEGGIO trial in PPMS87.
In RRMS, the treatment effect on brain atrophy correlates with the effect on disability
progression over 2 years, independently of the effect on active MRI lesions66.
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There are two types of brain volume-derived metrics (Table 3 and Supplementary
Tables 5 and 6): (i) metrics that calculate global brain atrophy, as either brain
parenchymal volume88 or fraction40 (which is the ratio of brain parenchymal volume
to the total volume within the brain surface contour), and their change over time, and
(ii) metrics that estimate regional volumes, such as white matter and grey matter, and
change thereof during the trial89.
The most widely used measures in the first group are the brain parenchymal fraction
(BPF), a segmentation-based technique that reduces the variability caused by
individual variation in brain size and has high test–retest reproducibility when
compared with raw brain volume90, and the percentage brain volume change (PBVC),
a registration-based difference map of brain contours over time91,92. BPF has been
used in studies such as the phase II trial with natalizumab in RRMS93 or the phase II
trial with interferon beta-1b in PPMS94. PBVC has been used in the phase III fingolimod
trials, i.e. the TRANSFORMS95 and FREEDOMS I14 and II47 studies, and the phase III
laquinimod trials, i.e. the BRAVO96 and the ALLEGRO13 studies.
In addition to the well-known technical sources of measurement error, such as
changes in magnet, gradients, coils, distortion corrections and image-contrast
changes that affect tissue segmentation, global atrophy metrics are susceptible to: (i)
the phenomenon of pseudo-atrophy, likely due to resolution of inflammation and
oedema and especially seen in patients on active treatment with greater gadolinium-
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enhancing lesion volume at baseline97,98, (ii) physiological (circadian) variations in
hydration status99, and (iii) smoking and other cardiovascular risk factors100.
The measures in the second group most commonly used are the grey and the white
matter volumes. The change in the volume of CSF (normalised by the total intracranial
volume) has also been used in phase III trials101,102, as an attempt to quantify indirectly
loss of neural tissue. A single phase II trial used the partial (central) cerebral volume,
a surrogate estimate of global atrophy89. The same trial showed that a reduction in
grey matter volume over time is greater than that in the white matter, and is less
affected by pseudoatrophy98, as other observational studies have also reported103.
Grey matter and thalamic volumes have also been used as additional outcome
measures in the phase III ALLEGRO study13. Therefore, if these partial volumes are
confirmed to show a greater change over time than global measures89,104,105, they will
result in higher sensitivity and a smaller sample size.
Spinal cord atrophy
Spinal cord atrophy is usually measured at the cervical level, and has been associated
with long-term development of motor disability, not only in progressive MS but also
in relapse-onset MS106,107. The rate of brain atrophy in MS is about 0.5% a year108,
whilst that of spinal cord atrophy has been shown to be higher, up to 2.2% a year in
SPMS109, suggesting that spinal cord atrophy may be a sensitive and meaningful
marker of neurodegeneration. Trials in PPMS or SPMS have used the change in cord
area54 as a secondary endpoint (Supplementary Ttable 7). However, there are
methodological factors that affect the noise of this measurement in multi-centre
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trials, mostly related to the limited spatial resolution of current MRI scanners relative
to the small cord size and cord movement. This translates into larger sample sizes than
those estimated from a single centre/scanner study110. Additionally, spinal cord
atrophy-related measures are calculated using semi-automated segmentation-based
methods, which are subject to inter-rater variability.
Novel imaging outcomes for neurodegeneration and remyelination
New outcomes have been proposed and used over the last 5 years to detect the effect
of drugs at a microscopic level. The advantage of such measures is that they are
expected to be more tissue-specific for the underlying pathophysiological processes
than conventional MRI measures, and, therefore, may detect changes reflecting the
underlying mechanisms of damage caused by the action of the experimental
medication. These novel measures may provide complementary information to that
given by conventional imaging endpoints and insights into the mechanistic efficacy of
the medication.
The most widely used measure is the change in magnetic transfer ratio (MTR) in the
whole brain13,16,111 (Table 3 and Supplementary Table 4). MTR changes are thought to
reflect the process of demyelination112 and remyelination113. Apart from whole brain
MTR, regional MTR, such as grey matter, white matter and lesional MTR, have also
been used (e.g., in the phase III, ALLEGRO trial in RRMS13).
Other measures –used mostly in the past– to show an effect of DMTs are metabolite
concentrations, estimated by MR spectroscopy imaging, such as N-Acetyl
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Aspartate13,114. Novel secondary outcome measures currently used in phase II trials in
secondary progressive MS are diffusion metrics parameters derived from NODDI
(Neurite orientation dispersion and density imaging), which estimate the
microstructural complexity of dendrites and axons in vivo115 and sodium imaging116
(https://clinicaltrials.gov/ct2/show/NCT02104661?term=oxcarbazepine+multiple+scl
erosis&rank=1, accessed 29/06/ January 2017).
Optical Coherence Tomography (OCT) measures axonal and neuronal loss within the
anterior visual pathway, which not only correlate with the visual function117,118, but
also reflect whole-brain process of neurodegeneration, especially in progressive
MS119. For that reason, it has been proposed as outcome measure in both optic
neuritis120 and non-optic neuritis MS trials, such as the PROXIMUS (add-on oral
oxcarbazepine vs. placebo in progressive MS)51, the FLUOX-PMS (oral fluoxetine vs.
placebo in monotherapy in progressive MS)121 and the ACTiMuS (bone marrow-
derived cellular therapy in progressive MS)122 trials. Please see Box 1 and
Supplementary Table 8 for more details on OCT-related outcome measures.
Combined clinical and MRI outcomes
Although the use of these types of measures emerged in MS trials in 2012 with the
CombiRx trial, the concept dates back to 2006, when Rio et al. showed that the
absence of relapses, disability, and inflammatory activity visible in the MRI (at certain
thresholds) after a given time on treatment would possibly indicate so minimal disease
activity that the risk of progression over a longer follow-up was negligible5. In 2014,
the outcome measure called “no evidence of disease activity” (NEDA)4 was defined as
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no relapses, no progression of disability, and no MRI activity (new/enlarging T2 lesions
and T1 gadolinium enhancing lesions). It had been initially defined as “Disease Activity
Freedom” (DAF) in the natalizumab AFFIRM trial123 and later re-termed as NEDA. It
has been recently used in phase III (Table 3 and Supplementary Table 1)29,30,101 and
phase II trials124,125. NEDA has also been used to compare the efficacy of medications
among trials; for example, AHSCT (autologous haemopoietic stem cell
transplantation) trials have shown a greater proportion of patients reaching the NEDA
status than other treatments126. Since brain volume loss reflects neurodegeneration
(the main determinant of progressive disability), it has been proposed to include it in
the definition of no evidence of disease activity (so-called “NEDA-4”), together with
relapses, MRI disease activity and clinical progression127.
Another combined endpoint is the event-free survival128, used in AHSCT trials, which
includes death as an outcome in addition to worsening of disability, relapse and new
MRI lesions, suggesting that combined measures can be designed to reflect the
expected efficacy and main adverse events of the drug.
The main objections to the use of these combined measures in clinical trials are that
the net effect of the experimental drug on the composite metric may be difficult to
interpret, if the effect on the different components is not the same, and there is
uncertainty in respect to the clinical relevance for individual cases53,129.
Outcomes in the clinical setting
In this section, we describe the clinical and neuroimaging measures that are currently
used in clinical practice.
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Clinical measures
In clinical practice, the most widely used clinical measures are related to the
occurrence of relapses and clinical progression, generally measured with the EDSS.
Relapses
The number of relapses occurred within a given time frame, usually 6-12 months, is
the clinical outcome most commonly used in clinical practice. It traditionally requireds
taking a medical history (which may could be associated with a recall bias) and
inspecting the clinical notes. The use of high-quality prospectively designed databases
can allow a more precise retrieval of relapse-related data in the clinic, successfully
enabling clinicians to assess treatment effects in clinical practice130,131. The presence
of relapses while on treatment, in combination with other factors such as EDSS
increase5 or MRI activity132, has been considered as a surrogate for future disability.
Along these lines, a recently published study from the MAGNIMS group, which
included 1,280 patients with RRMS on disease-modifying treatment, showed that the
presence of at least 2 relapses (or 1 relapse and ≥3 new T2 lesions) during the first 
year of treatment with interferon beta was associated with 48% risk of treatment
failure, defined as a confirmed EDSS worsening (≥1 point increase in EDSS if starting 
EDSS <5.5, or ≥0.5 increase if EDSS ≥5.5) or a switch to other therapies for lack of 
efficacy, and 29% risk of EDSS worsening over 3 years133.
Measures of disability
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The most common measure collected in clinical practice is the EDSS, which is used in
the outpatient clinics to assess the severity of clinical relapses and monitor treatment
effects. This scale is based on the standard neurological examination, which is part of
any clinical assessment, and clinicians are very familiar with the meaning of scores
above 4.0, which are based on walking ability. Therefore, the EDSS may be easy to
interpret clinically. However, as mentioned above, it has low intra- and inter-rater
reproducibility, especially for patients with mild to moderate disability. Besides, the
EDSS is not sensitive to important aspects of clinical progression, such as cognitive
dysfunction.
The MSFC is not used in the clinic as frequently as the EDSS or as often as in clinical
trials. One of the MSFC subtests, the PASAT test134,135, assesses the speed of (auditory)
information processing and calculation ability, and may compensate for the fact that
cognitive impairment is not captured by the EDSS. The TWT may be routinely
performed in the clinical setting when assessing patients’ ability to walk before and
after fampridine, to know whether the patient has benefited from the drug136.
However, the MSFC and its subtests have been designed to be used in clinical trials,
for group analyses, rather than to be used in the clinic, at the individual level39. To use
the MSFC or its components, it is required an a priori definition of a clinically
meaningful change. Besides, the reference population affects the values of the MSFC
z-scores, which means they cannot be easily interpreted in the clinic. Other limitations
include the practice effects137,138, which may influence the PASAT, and the fact that
the PASAT can be too distressful139.
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Considering the prevalence of cognitive dysfunction in MS and its impact on patients’
day-to-day lives, a committee of experts on cognitive dysfunction in MS agreed on the
need of regular cognitive assessments in patients with MS and proposed a brief
battery to be administered in the clinic, the Brief International Cognitive Assessment
for Multiple Sclerosis (BICAMS)140. This includes the Symbol Digit Modalities Test
(SDMT)141, which is also included in the Rao’s battery142, and is the most widely used
cognitive test. It measures attention and speed of information processing and lower
scores have been associated with the severity of white matter damage143. It has been
shown to be more valid and reliable than the PASAT, in part because it is a less
distressful test144. It requires a few minutes in total to be performed and the person
who administers the test does not require a specific training142. For all these reasons,
it is considered the best test to be administered if the time allocated to cognitive
assessment is very limited140. In addition to the SDMT, the BICAMS includes The
California Verbal Learning Test (Second Edition) and The Brief Visuospatial Memory
Test (Revised Version), and tests of verbal and visuospatial memory140. Apart from
the SDMT and the PASAT, the remainder of the tests included in the Rao’s battery can
also be used in the clinic, although training of the health professional is required142.
Finally, the Cogstate battery, a computerized tool made of simple rapid tests
measuring processing speed, attention, working memory, executive function and
verbal learning has been used in several neurological conditions, including MS145. In
general, cognitive tests in the clinic are difficult to administer due to time constraints.
Thus, more novel batteries such as the Cogstate, which can be self-administered
online, are potentially more promising in clinical practice. Additionally, it is neutral to
language and culture, being therefore preferable to other tests that may be influenced
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by education. Additional factors to consider are the effects of depression, anxiety and
fatigue on performanceBesides, age, education, depression and anxiety, and fatigue
may affect performance on all cognitive tests.
The PROMs discussed above can also be used in the clinic. In particular, the fatigue
scales, such as the FSSatigue Severity Scale60, the Modified Fatigue Impact Scale
(MFIS)146 or the Visual Analogue Scale for fatigue147, may be used. Other useful PROMs
are those that relate to depression, anxiety, pain or quality of life. Interestingly, in the
near future, the usefulness of PROMs in the clinic may substantially increase with the
help of the new technologies, since PROM-related information can be collected and
displayed to clinicians electronically.
Neuroimaging measures
In this section we review the T2 lesions, which is the most commonly used response
measure in the clinical setting, followed by brain atrophy and combined outcome
measures, which have recently started to emerge and are therefore also discussed.
Lesion-related measures
MRI has become a very usefulvital tool in clinical practice. According to international
recommendations, patients should be scanned regularly, usually at least once a
year148,149, especially if they are on treatment, or even more frequently, if they are on
certain treatments such as natalizumab, fingolimod or dimethyl fumarate, and
considered to be at risk of John Cunningham virus (JCV)-positive progressive multifocal
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leukoencephalopathy150. However, other time frames may still be possible and it is
not fully clear which is the best to adopt for routine, non-urgent MRI scans148,151.
International consensus recommends to perform a brain and/or a spinal cord MRI
scan when unexpected or atypical symptoms appear148,151. Ideally, when brain MRI is
used for monitoring of disease activity and treatment efficacy, it should be performed
on the same MRI system, using the same imaging protocol (i.e., the same pulse
sequences and spatial resolution) as the reference (baseline) scan148.
The most common response measure is the number of new (or enlarging) T2 lesions,
as compared with the previous scan, which is also referred as the number of active T2
lesions148. The number of active lesions is useful to monitor treatment response, since
the presence of new T2 lesions while on treatment has been associated to a worse
clinical outcome6,148 and may indicate the need for a treatment change6. The
occurrence of at least 3 new T2 lesions in the first year of interferon beta therapy was
associated with 27% risk of treatment failure (defined as confirmed EDSS increase or
switch to other therapies for lack of efficacy) and 22% risk of EDSS worsening over 3
years133. A disadvantage of the number of active T2 lesions as a response measure in
the clinic is that it requires previous MRI scans of the patient to be available for
comparison, and an experienced radiologist. Recently, the feasibility and reliability of
automated lesion segmentation algorithms using clinically acquired scans has started
to be assessed, showing promising results152. Therefore, in the near future, these
algorithms may allow the automatic computation of total T2 lesion load in the clinic,
potentially improving the monitoring of patients with MS.
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Another MRI measure used in the clinic is the number of Gd-enhancing lesions, which
provides information on acute inflammation and does not require the availability of
previous MRI scans. The predictive value of Gd-enhancing lesions seems to be
equivalent to that of the presence of new/enlarged (active) T2 lesions148. Additionally,
the enhancement, as happens with the presence of new lesions, has a role in
demonstrating the dissemination in time, as defined in the revised McDonald
criteria21. For the dissemination in space criteria, the recent MAGNIMS consensus
guidelines146 for the MRI criteria for the diagnosis of MS have suggested to include (i)
cortical lesions (together with the juxta-cortical lesions); and (ii) optic nerve lesions.
Yet at present, these lesions are looked for in selected, ad-hoc cases.
Over longer periods of observation, though, the number of new T2 lesions may be
preferable to Gd-enhancing lesions to detect subclinical disease activity, as the latter
only depicts disease activity in recent weeks. Other reasons for this include the higher
costs associated to gadolinium usage and the fact that gadolinium infusions entail
some rare medical risks, the most serious of which is the nephrogenic systemic
fibrosis, although the risk may depend on the type of the gadolinium-containing
contrast media153. Gadolinium can also deposit in the brain154, yet the clinical
consequences of this deposition remain unknown. Gadolinium administration is not
recommended in routine MRI safety monitoring of patients receiving natalizumab155.
Brain atrophy and other MRI measures
The use of atrophy in the clinic is currently controversial156-158. Although the
contribution of brain atrophy to clinical and cognitive deficits is well-established at a
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group level148, there are several factors that may limit the application of atrophy in
the clinical setting. These are: the lack of normative values for brain volume changes
in healthy individuals and in patients with MS, the intra-individual variability, due to
physiological variations (for example, dehydration, alcohol consumption), the
presence of co-morbidities and disease-related factors, such as the initiation of a DMT,
which may induce “pseudoatrophy”97,103,148. There a number of current techniques in
development to try to overcome these issues: Jacobian integration159 or lateral
ventricle volume estimation160, using T1-weighted or T2-weighted images,
respectively, are being developed to improve the reliability of atrophy metrics in the
clinic. It is important to bear in mind that Ddifferences in the MRI hardware and
software packages used for analysis or processing can generate variability in brain
atrophy measures148. Additionally, ; MRI scanner upgrades or replacements can make
the images acquired at different time points non-less comparable161. Ideally, of
course, the same MS patient should be scanned on the same scanner and with the
same protocol, whenever possible.
Combined clinical and MRI measures
A MAGNIMS study mentioned above showed that combining MRI activity with clinical
relapses during the first year of treatment with interferon may identify patients who
have a high risk of treatment failure and EDSS worsening in the short term133. In actual
fact, escalation from first line DMT to a second line DMT is routinely advised in the
clinical setting as a consequence of clinical and radiological evidence of disease
activity.
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There is no strong evidence to support the use of NEDA in clinical practice. In 2015
Rotstein et al. found, in a longitudinal study carried out in 219 patients, that those
who maintained NEDA for 2 years had a very high probability (78.3%) of not showing
any disability progression (defined as an increase in EDSS of >0.5 points), at 7 years of
follow-up. However, a recent study that included 517 consecutive MS patients has
found that achieving NEDA after the first two years of follow-up was not associated to
a better prognosis at 10-year follow-up162. Although this was an observational study
carried out in a heterogeneous cohort, where not all patients were on treatment
(which may have been adjusted based on MRI and clinical findings), NEDA might not
be a useful measure to predict a long-term outcome. In fact, it is likely that despite its
high positive predictive value, NEDA has a low negative predictive value, so losing
NEDA during the follow-up does not necessarily mean that prognosis is significantly
worse, whereas maintaining NEDA is definitely a good prognostic marker. The
implementation of NEDA-4, which includes brain atrophy, in the clinical setting is
associated with the limitations described above and has not been validated for use in
individual patients.
Translation from Trials to Clinical usage
We have demonstrated in the two sections above that most outcome measures used
in clinical trials are not used in routine practice, and when they are, their use is limited
and simplified. This is because in the clinical trials they are used for investigating drug
effects at a population level, whilst in the clinical setting they are employed at the
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individual level to assess the response to the medication (response measure), monitor
patients (monitoring measure), or guide treatment decisions. In this section, we will
compare the outcomes in clinical trials versus those used in the clinic. Although a
translation of outcome measures used to demonstrate the effects of the drug to the
clinical setting should be sought, there are elements in the clinical practice that go
beyond treatment efficacy and influence patient management, such as patient’s
perception of risks and patient’s priorities. An attractive field of outcome measure
which may overcome some barriers to the translation of outcome measures from
trials to the clinical setting, such as the lack of time in the outpatient clinics, concerns
the development of novel outcome measures driven by the introduction of electronic
devices.
Outcomes in clinical trials versus monitoring in the clinic
Clinical or MRI outcome measures in clinical trials must be sensitive enough to be able
to detect subtle, though highly relevant, treatment changes. This is especially
important when the trial aims to compare a new drug not with placebo, but with
another active drug39. In clinical trials, if the outcome measures are specific but not
too sensitive, there may be a high risk of a falsely negative result, ultimately implying
that a potentially efficacious drug may never be launched. Response measures in the
clinic, instead, should probably be more specific than sensitive, since the
consequences of prematurely (or incorrectly) starting or stopping a drug may have
harmful consequences for the patient.
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In clinical trials, clinical and MRI outcomes do not need to be meaningful at the
individual level, as far as they are meaningful at the group level. For example, the
outcome ‘changes in MSFC z-scores’ is only meaningful at the group level, and its
usefulness stems from the comparison between treatment groups. In particular, it has
been suggested that an increase in at least 20% in MSFC score or its subscores is a
clinically relevant increase48. Instead, in the clinic, any type of monitoring instrument
(or response measure) must be meaningful at the individual level. Importantly, in both
clinical trials and the clinical setting, outcomes must reflect relevant functional or
structural/pathological aspects of the condition and must be reproducible.
Regarding combined outcomes, whereas they have been extensively and successfully
used in clinical trials, their use in the clinic will again depend on their meaningfulness
at the individual level. Some of these combined outcomes, such as NEDA, have mainly
been used in the trials, although they could be valid at the individual level and used in
the clinic. In fact, when the factors associated with treatment response started to be
defined5, the underlying concept was the same as NEDA, although with a less
restrictive threshold.
In relation to PROMs, their implementation in the clinic may be hampered by their
inter and intra-patient variability. In clinical trials, this high variability may be
compensated by large numbers. Further limitations for the use of PROMs in the clinic
include that they can be time-consuming, that there is a very large number of
measuring tools available without a clear evidence of superiority of one over the
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others, and that the large amount of information that is produced needs to be
interpreted and turned into useful data.
Another difference between outcomes in clinical trials and in the clinic is that in clinical
trials there seems to be a trend towards a greater number of outcomes used over time
(Figure 2a), whereas this is not happening in the clinic, where the EDSS score has been
dominant for long time already. Interestingly, this increase in the number of trial
endpoints is accompanied by a clear increase in the number of participants per trial
(Figure 2b), which all together may be considered as an attempt to increase the power
of the trial to detect a treatment effect, without prolonging the trial duration (Figure
2c).
Finally, we need to acknowledge that patients and clinicians may have a different
perspective on what outcomes are relevant and desirable. For example, a comparison
of the opinions and judgements of clinicians with those of patients utilising the short-
form-36 showed that patients tend to prioritise general health and vitality, mental
health, and emotional role limitation, whilst clinicians consider that physical disability,
bodily pain and social functions are more important to the patient163. Undoubtedly,
these are also factors that need to be taken into account when translating outcomes
from trial to the clinic setting. Ultimately holistic approachesThus, rather holistic
approaches accommodating both patients’ and clinicians’ priorities, are probably
preferred in the clinical setting, whereas this may not be a priority in clinical trials.
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Conclusions
There are now over a dozen agents that can reduce the inflammatory component of
MS, but there is an unmet and urgent need to treat progressive MS and promote
tissue repair and neuroprotection. The availability of clinical and imaging measures in
trials is of the utmost importance to ensure the detection of drug efficacy – nowhere
more needed than in phase II trials of progression. The choice of the best set of
outcomes for a given trial may be difficult because of the large amount of possible
response measures described and used in the literature. Yet all trials should surely
include clinical measures of disease progression, ideally based on the EDSS, for which
there is a high experience, and other motor and/or cognitive measures, for which
there is less experience, but which potentially have a higher sensitivity to capture
subtle but relevant changes in disability. Besides, tThe time periods used to decide
confirmed disability progression should be as long as possible, even 12 months if
possible. Neuroimaging outcomes should include more traditional measures such as
those related to lesion load, and also measures of brain atrophy. The inclusion of more
novel measures is encouraged and their choice will possibly depend on the mechanism
of action of the drug or the mechanistic research question that needs to be answered.
In the clinic, the choice of response measures determines the decisions about
treatments and patient management. Although it would be ideal to use in the clinic
the same tools to measure treatment response as those used in the clinical trial that
led to licencingdrug being licenced, at present, most of the endpoints used in trials
cannot be used as response measures in the clinical setting. This is due to technical,
financial and logistic barriers, such as the time required to obtain these measures,
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training/standardisation, and the fact that their clinical meaning, when used at the
individual level, is very limited. Most importantly, validated cut-off values that predict
a favourable outcome in the long-run are lacking.
The use of PROMs and combined measures is important in both settings, since they
capture the impact (and effects) of the intervention on clinical disability, MRI
parameters, daily activities and quality of life. Further studies are needed to assess
the reliability, accuracy and robustness of the combination of PROMs and objective
(clinical and neuroimaging) measures, with the potential to comprehensively capture
the intrinsic multidimensional nature of MS.
Review criteria
For this review paper, we performed searches in PubMed and www.clinical.trials.gov
using the following search terms: ‘multiple sclerosis’, ‘phase trial’, ‘EDSS’,
‘progression’, ‘relapse rate’, ‘MRI’, ‘neuroimaging’, ‘OCT’, ‘PROMS’, ‘cognition’
(clinical trials sections); and ‘multiple sclerosis’, ‘EDSS’, ‘progression’, ‘relapse rate’,
‘MRI’, ‘neuroimaging’, ‘OCT’, ‘PROMS’, ‘cognition’, ‘electronic devices’. We did not
include any date limitations (the last date that we searched was June 2017). Papers
were included in this review only if they were written in English. For the clinical trial
section, only phase II or phase III controlled trials were included (uncontrolled and/or
phase 0/I trials were not included).
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Table 1. Main relapse-related and progression-related outcome measures used in
phase III trials
Outcome measure
Number of trials Trials/References
(in alphabetical order)







Relapse-related outcome measures – CIS trials
Time to CDMS 6* 7 BENEFIT*21, CHAMPS*164, ETOMS*75,
ORACLE MS*165, PreCISe*88, REFLEX22,
TOPIC*23
%CDMS 0 5 BENEFIT21, CHAMPS164, ETOMS75, REFLEX22,
TOPIC23
Time to McDonald MS 2* 3 BENEFIT*21, REFLEX*22, TOPIC23
% McDonald MS 0 3 BENEFIT21, REFLEX22, TOPIC23
Relapse-related outcome measures – MS trials
Time to confirmed
relapse
1* 18 BEYOND11, CLARITY166, CombiRx101,
CONFIRM167, DEFINE111, EudraCT 2006-
004937-13168, EUSPMS169, EVIDENCE170,
FREEDOMS14, GALA171, NASPMS41, PRISMS17,
REGARD*172, SIMCOMBIN173,
SPECTRIMS76,77, TEMSO102, The copolymer 1







ARR 23* 41 ADVANCE*16, AFFIRM*123, ALLEGRO*13,
ARIANNA40, BEYOND11, BRAVO*96, CARE-MS
I*29, CARE-MS II*30, CLARITY*166,
CombiRx*101, CONFIRM*167, DECIDE*174,
DEFINE111, ESIMS55, ETOMS75, EudraCT 2006-
004937-13*168, European/Canadian
glatiramer acetate study175, EUSPMS169,
EVIDENCE170, FORTE*176, FREEDOMS*14,




SPECTRIMS76,77, TEMSO*102, TENERE15, The
copolymer 1 multiple sclerosis study*31, The
IFNb multiple sclerosis study*180, The Nordic
SPMS study64, TOPIC23, TOWER*181,
TRANSFORMS*95
ARSR 0 6 ALLEGRO13, BEYOND11, GALA171, MAESTRO44,
PRISMS17, SPECTRIMS76,77, The IFNb multiple
sclerosis study180
% at least one relapse 1* 9 ADVANCE16, BEYOND11, CombiRx101,
CONFIRM167, DEFINE*111, ESIMS55, EudraCT
2006-004937-13168, PreCISe88, TENERE15
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% relapse free 2* 28 AFFIRM123, ALLEGRO13, ARIANNA40,
BEYOND11, BRAVO96, CARE-MS I29, CARE-MS
II30, CLARITY166, CombiRx101, DECIDE174,
EudraCT 2006-004937-13168, EVIDENCE*170,
FORTE176, FREEDOMS14, FREEDOMS II47,
GALA171, GATE81, NASPMS41, PRISMS17,
REGARD172, SENTINEL179, SIMCOMBIN173,
The copolymer 1 multiple sclerosis study31,
The IFNb Multiple Sclerosis Study*180, The







time between first and
second relapse
1* 2 BEYOND*11, SPECTRIMS76,77
Progression-related outcome measures
Change in EDSS 0 21 ARIANNA40, CARE-MS I29, CARE-MS II30,
ESIMS55, ETOMS75, EudraCT 2006-004937-
13168, EUSPMS169, FREEDOMS14, FREEDOMS
II47, GATE81, MAESTRO44, NASPMS41,
OLYMPUS25, PRISMS17, PROMISE182, The
Copolymer 1 Multiple Sclerosis study31, The
IFNb Multiple Sclerosis Study180, The Nordic
SMPS Study64, TOPIC23, TOWER181,
TRANSFORMS95
Change in MSFC or its
subscores (PASAT,
TWT, 9HPT)
1* 11 CARE-MS I29, CARE-MS II30, CombiRx101,
CUPID65, FREEDOMS14, FREEDOMS II47,
IMPACT*43, MAESTRO44, OLYMPUS25,
PROMISE182, TRANSFORMS95,
Change in other clinical
scales (physical
disability)
0 3 ETOMS75, PRISMS17, The Nordic SMPS
Study64
Change in other clinical
scales (cognitive
disability)
0 2 IMPACT43, MAESTRO44
% of 3m-CDP in EDSS 2* 23 ADVANCE16, AFFIRM*123, ALLEGRO13,
BEYOND11, BRAVO96, CONFIRM167,





The Copolymer 1 Multiple Sclerosis study31,
TOPIC23
% free from 3m-CDP in
EDSS
0 7 CLARITY166, FREEDOMS14, FREEDOMS II47,
PRISMS17, The Copolymer 1 Multiple
Sclerosis study31, TOWER181, TRANSFORMS95
% of 6m-CDP in EDSS 0 10 ARIANNA40, BRAVO96, CARE-MS I29, CARE-MS
II30, CombiRx101, INFORMS54, MAESTRO44,
OLYMPUS25, REGARD172, The Nordic SMPS
Study
% free from 6m-CDP in
EDSS




0 2 CARE-MS II30, The Copolymer 1 Multiple
Sclerosis study31
% 3m-CDP in MSFC
subscores
0 2 ESIMS55, INFORMS54
% 6m-CDP in MSFC
subscores
0 1 INFORMS54
% with 20% worsening
in MSFC
0 1 ARIANNA40
Time to EDSS 7.0 0 1 EUSPMS169
Time to 3m-CDP in
EDSS








Time to 6m-CDP in
EDSS
6* 12 ALLEGRO13, BRAVO96, CARE-MS I*29, CARE-
MS II*30, CUPID*65, FREEDOMS14,
INFORMS54, MAESTRO*44, NASPMS*41,
ORATORIO26, SIMCOMBIN173, The Nordic
SMPS Study*
Time to 3m-CDP in
MSFC subscores
0 2 ESIMS55, INFORMS54





0 4 ALLEGRO13, EUSPMS169, PRISMS17, The




1* 5 CARE-MS I29, CARE-MS II30, CombiRx101,
ESIMS55, INFORMS*54
Footnote table 1. The primary endpoint of the ARIANNA study40 was the changes in
brain volume fraction (i.e. this study did not have a clinical primary endpoint).
Abbreviations: ARR: annualised relapse rate; ARSR: annualised rate of severe relapses;
CDMS: clinically defined multiple sclerosis; CDP: confirmed disability progression;
EDSS: expanded disability status scale; 9HPT: nine-hole peg test; MSFC: multiple
sclerosis functional composite; NECA: No evidence of clinical activity; PASAT: paced
auditory serial addition test; TWT: 25-foot timed walk test.
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Table 2. Main patient-reported outcome measures used as phase III trial endpoints
Outcome measure Number of trials Trials/References(in alphabetical order)
Arm index 2 PRISMS17, The Nordic SMPS Study
PRIMUS 1 INFORMS54
EQ-5D/MSQoL-54 4 BENEFIT21, FREEDOMS II47, INFORMS54, MAESTRO44
FIS 5 INFORMS54, TEMSO102, TENERE15, TOPIC23, TOWER181
MSWS-12 2 CUPID65, INFORMS54
MSIS-29 2 CUPID65, DECIDE174
SF-36 1 TOWER181
TSQM 1 TOWER181
Footnote table 2. Abbreviations: FIS (or UFIS): Unidimensional Fatigue Impact Scale;
MSIS-29: Multiple Sclerosis Impact Scale – 29 items; MSWS-12: Multiple Sclerosis
Walking Scale; SF-36: Short Form 36 Health Survey; PRIMUS: Patient-Reported Indices
for Multiple Sclerosis; TSQM: Treatment Satisfaction Questionnaire for Medication,
with domains for Effectiveness, Side-Effects, Convenience and Global Satisfaction.
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Table 3. Main MRI outcome measures used in phase III trials




# new T2 lesions 8 AFFIRM123, BENEFIT21, BEYOND11, European/ Canadian
Glatiramer Acetate Study, FORTE176, IMPACT43, PreCISe88, The




# new or enlarging
T2 lesions
28 ADVANCE16, AFFIRM123, ALLEGRO13, BRAVO96, CARE-MS I29,
CARE-MS II30, CHAMPS164, CLARITY166, CONFIRM167, CUPID65,
DECIDE174, DEFINE111, ESIMS55, ETOMS75, EudraCT 2006-004937-
13168, EVIDENCE170, FREEDOMS14, FREEDOMS II47, GALA171,
INFORMS54, MAESTRO44, ORACLE MS165, PRISMS17, REGARD172,
SENTINEL179, SIMCOMBIN173, TRANSFORMS95, TEMSO102
Change in #T2
lesions
4 CombiRx101, PreCISe88, TEMSO102, TOPIC23
Change in T2 lesion
volume
33 ADVANCE16, AFFIRM123, BENEFIT21, BEYOND11, CARE-MS I29,
CARE-MS II30, CHAMPS164, CLARITY166, CombiRx101, CONFIRM167,
DECIDE174, DEFINE111, ESIMS55, ETOMS75, European/Canadian
Glatiramer Acetate Study175, EUSPMS169, FREEDOMS14,
FREEDOMS II47, IMPACT43, MAESTRO44, MSCRG178, NASPMS41,
OLYMPUS25, ORATORIO26, PRISMS17, PROMISE182, REGARD172,
SIMCOMBIN173, SPECTRIMS76,77, TEMSO102, The IFNb Multiple
Sclerosis Study180, TOPIC23, TRANSFORMS95
Gadolinium-enhancing lesion-related outcome measures
# Gd-enhancing T1
lesions at follow-up
36 ADVANCE16, AFFIRM123, ALLEGRO13, BENEFIT21, BEYOND11,
BRAVO96, CARE-MS I29, CARE-MS II30, CHAMPS164, CLARITY166,
CONFIRM167, DECIDE174, DEFINE111, ESIMS55, ETOMS75, EudraCT
2006-004937-13168, European/Canadian Glatiramer Acetate
Study175, FORTE176, FREEDOMS14, FREEDOMS II47, GALA171,
GATE81, IMPACT43, INFORMS54, MAESTRO44, MSCRG178,
NASPMS41, ORACLE MS165, PROMISE182, REGARD172,
SENTINEL179, SPECTRIMS76,77, TEMSO102, The IFNb Multiple
Sclerosis Study180, TOPIC23, TRANSFORMS95
% patients with Gd-
enhancing lesions
at follow-up
9 ARIANNA40, CLARITY166, FREEDOMS14, FREEDOMS II47,





11 AFFIRM123, BENEFIT21, BEYOND11, CONFIRM167, DEFINE111,
European/Canadian Glatiramer Acetate Study175, IMPACT43,
MSCRG178, REGARD172, TOPIC23, TRANSFORMS95




14 ADVANCE16, AFFIRM123, ALLEGRO13, BENEFIT21, CLARITY166,
CONFIRM167, CUPID65, DECIDE174, DEFINE111, GALA171,
INFORMS54, TEMSO102, TOPIC23, REGARD172
Change in T1 lesion
volume
14 ADVANCE16, AFFIRM123, BENEFIT21, BEYOND11, DECIDE174,
DEFINE111, ESIMS55, European/Canadian Glatiramer Acetate
Study175, FREEDOMS14, FREEDOMS II47, REGARD172,
SIMCOMBIN173, TEMSO102, TRANSFORMS95














13 ADVANCE16, BENEFIT21, CLARITY166, CombiRx101, ETOMS75,
EudraCT 2006-004937-13168, FREEDOMS14, FREEDOMS II47,









25 ADVANCE16, AFFIRM123, ALLEGRO13, ARIANNA40, BEYOND11,
BRAVO96, CARE-MS I29, CARE-MS II30, CONFIRM167, CUPID65,
DEFINE111, FORTE176, FREEDOMS14, FREEDOMS II47, GALA171,
ESIMS55, INFORMS54, MAESTRO44, OLYMPUS25, ORATORIO26,
PreCISe88,REGARD172, SIMCOMBIN173, TOPIC23, TRANSFORMS95
Change in GM
volume/fraction
3 ALLEGRO13, CombiRx101, TEMSO102
Change in WM
volume/fraction






4 ADVANCE16, ALLEGRO13, CONFIRM167, DEFINE111
Change in WM MTR 1 ALLEGRO13
Change in GM MTR 1 ALLEGRO13
Change in T2 lesion
MTR
1 ALLEGRO13
Changes in the ratio
NAA/creatinine
1 ALLEGRO13
Combined MRI and clinical outcomes
NEDA (no evidence
of disease activity)
3 CARE-MS I29, CARE-MS II30, CombiRx101
Footnote table 3. Abbreviations: CSF: cerebrospinal fluid; Gd: gadolinium; MTR:
magnetisation transfer ratio; NAA/Cr: N-acetyl aspartate-creatine ratio;
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Table 4 (New): Summary of the strengths and weaknesses of the main outcome
measures
Outcome measure
Used in clinical trials
(T), in the clinic (C) or
in both (B)
Strengths
In relation to their use in clinical
trials (T), in the clinic (C) or in both
(B)
Limitations
In relation to their use in clinical




# of relapses (C) or ARR
(T)
Easy to compute and understand (B) Only relevant for relapsing forms
of MS (B)
No specific for MS severity (B)
# of severe relapses (C)
or ARSR (T)
May reflect severity of MS relapses
(B)
High inter-site variability due to




In line with the concept of no
disease activity, useful for trials with
powerful drugs (T)
Highly dependent on trial
duration, with statistical




Useful in CIS trials (T) Only relevant for relapsing forms
of MS (B)
No specific for MS severity (B)
Time to treatment
failure (T)
Accounts for efficacy, safety and
tolerability of the drug (i.e. reflects
real-life scenario) (T)
Unspecific (T)
Measures of disability progression
Change in EDSS and
EDSS scores at follow-
up (B)
Easy to understand by the MS
community (B)
EDSS score changes do not




EDSS is not sensitive to upper
limb or cognitive disability (B)
Low inter- and intra-rater
reproducibility (especially if low
EDSS scores) (B)
Change in MSFC or its
subscores and MSFC
scores at follow-up (B)
No specific training required (B)
Sensitive to upper limb (NHPT) and
cognitive (PASAT) functions (B)
In the clinic, TWT is useful to
monitor drug effects, such as
fampridine (C)
Designed to be used in trials, at
group level (i.e. reduced
usefulness in the clinic) (C)
Definition of clinically meaningful
change is required (mainly CT)
Choice of a reference population
affects z-scores (T)
Practice effects (B)
PASAT may be stressful (B)
Change in other clinical
(mainly cognitive)
scales (B)
For SDMT, no specific training
required (B)
Sensitive to cognitive impairment (B)
Training may be required for
cognitive tests (exc. SDMT) (B)
Reference population often
needed to interpret results (C)
Age, anxiety, fatigue and
education may influence results
(B)
% of 3m/6m-CDP in
EDSS (T)





Highly dependent on trial
duration, with statistical
implications (T)
% free from 3m/6m-
CDP in EDSS (T)
Easy to understand by the MS
community (T)
In line with the concept of no
disease activity, useful for trials with
powerful drugs (T)
Underestimation of % patients
free from long-term disability
accumulation (T)





Useful to detect improvements of
disability, largely overlooked in MS
trials (T)




% 3m/6m-CDP in MSFC
subscores (T)
Strengths of the MSFC-related
outcome measures and outcome
measures that consider progression
as a binary phenomenon (see above)
(T)
Limitations of the MSFC-related
outcome measures and outcome
measures that consider %
patients with disability
progression (see above) (T)
Time to 3m/6m-CDP in
EDSS/MSFC and time




Informative about the effect of the
drug on immediate risk of CDP (as
opposed to ‘% patients with CDP’,
which considers the risk over a






Higher sensitivity than individual
components to detection of
disability progression, implying a
reduction in required sample
sizes/trial durations (T)
Reduction of the risk of type I error
(T)
NECA: comprehensive measure of
real-life treatment effect (B)
Individual components cannot be
analysed independently, unless




related to treatment (T)
PROMs
All PROMs (B) Information comes directly from the
patient (B)
Information is subjective and
may fluctuate within subjects (B)
NEUROIMAGING & NEUROPHYSIOLOGICAL OUTCOME MEASURES
Outcome measures related to focal lesions
T2-lesion-related
outcome measures (B)
Information on new and cumulative
inflammatory activity (B)






Information on recent inflammatory
activity (within 3-6 weeks prior scan
date) (B)





May inform about tissue destruction
secondary to inflammation and
repair (B)
The delineation of hypointense




More sensitive than new T2 or
gadolinium-enhancing lesions
separately (B)
Their computation is slightly
more complex than new T2 or
gadolinium-enhancing lesions (B)













Reflect neurodegeneration in the
spinal cord, highly related to motor
disability (T)
Limited spatial resolution, which
hampers multi-centre studies (T)
Current segmentation methods
are semi-automated, implying








features of brain damage,




protocols and analysis methods
still in progress (T)
OCT (B) Information on axonal and neuronal
loss within the anterior visual
pathway (related to
neurodegeneration) (B)
Useful to monitor drugs’ side effects
(fingolimod) (B)





NEDA: comprehensive measure of
real-life treatment effect (B)
Difficult interpretation of the net
effect of drugs on the outcome
measure (T)
Reduced usefulness in the clinic
(high positive predictive value
but low negative predictive
value) (C)
VEPs (T) May reflect remyelinating processes
secondary to experimental drugs (T)
Not sensitive enough to monitor
disease progression (B)
Footnote table 4. Abbreviations: ARR: annualised relapse rate; B: both clinical trial and
clinical setting; ARSR: annualised rate of severe relapses; C: clinical setting; CDMS:
clinically defined multiple sclerosis; CDP: confirmed disability progression; EDSS:
expanded disability status scale; Gd: gadolinium; 9HPT: nine-hole peg test; MSFC:
multiple sclerosis functional composite; MTR: magnetisation transfer ratio; NECA: No
evidence of clinical activity; NEDA: No evidence of disease activity; PASAT: paced
auditory serial addition test; OCT: optical coherence tomography; PET: positron
emission tomography; PROMs: patient-reported outcome measures; SDMT: symbol




Box 1 (New). Novel and future outcome measures
Possible future clinical outcomes include those obtained through the utilisation of ‘smart’
technology such as wearable sensors have started to be developed for their use mainly in
the clinic. Wearable sensors are electronic devices that can be attached to the body and
record information about the user’s quantity and quality of movement. This portable
technology can provide objective and quantitative data184 which may be useful to detect
response to therapeutic interventions in the real life. Besides, several strategies have been
developed to maximise the sensitivity to disease progression of current disability scores.
These include re-baselining the EDSS score according to both screening and first visits, and
using new metrics such as the area under the curve described by the disability score
trajectories over time131.
Possible future imaging outcomes include markers of remyelination, such as within-lesion
MTR185 or the level of [11C]PIB binding186, obtained with positron emission tomography
(PET). Markers of chronic inflammation, such as the presence of slowly enlarging lesions187,
and microglial activation, such as and level of TSPO binding188-190, also obtained through
PET, can be used as future outcome measures too. These potential outcomes can bring us
closer to achieving precision medicine189.
Advanced OCT techniques provide quantitative measurements of both retinal nerve fibre
layer (RNFL, axonal) and ganglion cell layer (GCL, neuronal) loss in vivo, representing an
ideal model for assessing the neuroprotective effects of novel agents118. Possible
advantages of OCT in trials are that the evaluation of the retinal structure might predict the
clinical response to treatment191 and the risk of developing specific ocular side effects192.
Finally, future neurophysiological outcomes would include visual evoked potentials and
multimodal evoked potentials, which have shown some ability to predict clinical evolution
in patients with MS193-195. Change in full-field VEPs latency at week-24 has been used as
the primary outcome measure in a phase 2 trial assessing the efficacy of a remyelinating
therapy after the first episode of optic neuritis196
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Box 2. Main clinical and neuroimaging outcomes and derived outcome measures
used in the clinical setting
Clinical outcomes
Relapses
 Number of relapses over a period of time
EDSS
 EDSS score at a given time point
 Change in EDSS score over a period of time
TWT
 TWT score (measured in seconds) at a given time point
9HPT
 9HPT score (measured in seconds) at a given time point
PASAT
 Number of successes (maximum: 60) during the test
SDMT
 Number of successes (no maximum) during the test (usually 1 minute)
FIS/FSS/MFIS
 Score at a given time point
Neuroimaging outcomes
Brain T2 lesions
 Number of lesions at a given time point
 Number of new or enlarging lesions
Brain Gd-enhancing lesions
 Number of lesions at a given time point
Brain non-enhancing T1 lesions
 Number of lesions at a given time point
Brain cortical lesions (in DIR sequences)
 Number of lesions at a given time point
Spinal cord T2 lesions
 Number of lesions at a given time point
Abbreviations:
DIR: double inversion recovery; EDSS: Expanded Disability Status Scale; FIS (or UFIS):
Unidimensional Fatigue Impact Scale; FSS: fatigue severity scale; 9HPT: Nine-Hole Peg
Test; MFIS: modified fatigue impact scale; PASAT: Paced Auditory Serial Addition Test;
SDMT: symbol digit modalities test; TWT: 25-Foot Timed Walk Test;
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Figure legends
Figure1: Number of phase III trials over time in relapsing and progressive MS
Figure 1 (legend).
This figure illustrates the increase in the number of phase III clinical trials carried out
over the last five years, especially in relapsing MS patients. Abbreviations: CIS:
clinically isolated syndrome; MS: multiple sclerosis; PPMS: primary progressive
multiple sclerosis; SPMS: secondary progressive multiple1 sclerosis.
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Figure 2: Trends over time in phase III trials
2a: Evolution of number of trial endpoints over time;
2b: Evolution of number of participants per trial over time;
2c: Evolution of trial duration over time.
Figure 2 (legend).
This figure illustrates the evolution over time of (a) the number of trial endpoints per
trial; (b) number of participants per trial; (c) trial duration. As can be observed, there
has been a clear increase in the number of trial endpoints per trial and the number of
participants per trial over the last 5-10 years, whereas the trial duration has remained
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(a) ARR refers to mean ARR per each group; it includes confirmed relapse rate, which
includes rate of relapses with confirmed increase in EDSS (Voskuhl et al., Lancet
Neurol 2016) and also adjusted mean relapse rate (Vollmer et al., J Neurol 2014)
(b) No detailed figures provided
(c) Cognitive impairment was defined on the number of failed tests, as mild (one to
two tests failed) or moderate–severe (three or more tests failed)
(d) Defined as ≥7.5 points increase in MSIS-29 
(e) CDP: Confirmed disability progression was defined as an increase of Expanded
Disability Status Scale score of at least 1·0 point for patients with a baseline score of
1·0 or more, or an increase of at least 1·5 points for patients with a baseline score of
0, confirmed after 12 weeks. For the rest, EDSS increase of ≥1 point if EDSS ≤5.5; 
EDSS increase of ≥0.5 point if EDSS > 5.5;  
(f) Includes adjusted MSFC z-score; also it may include values obtained at an early
termination time point if this occurred after 12 months.
(g) Includes time to sustained accumulation of disability, which is considered as
increase in 1 point in EDSS sustained for a minimum of 12 weeks (Confavreux et al.,
Lancet Neurol 2014, TOWER trial)
(h) No MRI activity includes: no new/enlarging lesions and no gadolinium-enhancing
lesions
(i) Includes relapses requiring hospitalization/IV steroids (Comi et al., NEJM 2012,
ALLEGRO study)
(j) Adjusting for baseline values of MSFC z-score, ANCOVA model
(k) Mean change reported, unless otherwise specified
(l) It includes ‘at least 1 major relapse’
(m) The authors also estimated the proportion of patients with: i) at least one MS-
related admission to hospital; ii) at least 1 MS-rekated steroid course
(n) The results shown refer to the comparative phase (0-12m) of the trial, where half
of the patients were receiving IFN beta-1a IM 30mcg/week and the other half IFN
beta-1a SC 44mcg tiw.
(o) p-value not specified
(p) this analysis refers to disability progression in both hands
(q) worsening in 9HPT is defined as deterioration greater or equal to 20%
(r) confirmed at 2 months
(s) mean number of relapses per patient during the trial/2 years (duration of trial)
(t) defined as 2-step increase (sustained for 3 months)
(u) in this context, this outcome measure (risk ratio or odds ratio) is equivalent to
hazard ratio in the survival model
(v) timing for CDP not specified. Assumed 3 months
(w) this study looked at disability progression at the end of FU, so it is possible that
just progression confirmed at just 3 months is also included here
(x) This refers to McDonald 2005 criteria
Abbreviations. BD: twice per day; CDP: confirmed disability progression; CI:
confidence interval; eod: every other day; FU: follow-up; GA: glatiramer acetate; HR:
34
hazard ratio; IA & AHSCT: immunoablation and autologous haemopoietic stem-cell
transplantation; IFN: interferon; IQR: interquartile range; MIU: million international
units; MSCT: mesenchymal stem cell transplantation; MSFC: Multiple Sclerosis
Functional Composite; MSIS-29: Multiple Sclerosis Impact Scale – 29 items; PO: per
oral; RFSS: Regional Functional System Score; SC: subcutaneous; SF-36: Short Form
36 Health Survey (SF-36); SNRS: Scripps Neurological Rating Scale; TDS: three times
per day; tiw: three times in a week; TSQM: Treatment Satisfaction Questionnaire for
Medication, with domains for Effectiveness, Side-Effects, Convenience and Global
Satisfaction
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22mcg SC/week:
mean time (95%




time (95% CI) 252







































CIS (n=517) IFN beta-1a
44mcg SC/week
vs. placebo:
HR (95% CI) 0·53
(0·35 to 0·79), p =
0.0023;
IFN beta-1a
44mcg SC tiw vs.
placebo: HR (95%
CI) 0·48 (0·31 to
0·73), p = 0.0004;
IFN beta-1a
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7mg: 62%, p (vs.
placebo) = 0.0020;
Teriflunomide
14mg: 64%, p (vs.
108 weeks
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CIS (n=308) IFN beta-1a
22mcg SC/week:
median (IQR) 0 (-1
to 0); Placebo:
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CIS (n=308) IFN beta-1a
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median (IQR) 0 (-1
to 2); Placebo:





























(a) ARR refers to mean ARR per each group; it includes confirmed relapse rate, which
includes rate of relapses with confirmed increase in EDSS (Voskuhl et al., Lancet
Neurol 2016) and also adjusted mean relapse rate (Vollmer et al., J Neurol 2014)
(b) No detailed figures provided
(c) Cognitive impairment was defined on the number of failed tests, as mild (one to
two tests failed) or moderate–severe (three or more tests failed)
(d) Defined as ≥7.5 points increase in MSIS-29 
(e) CDP: Confirmed disability progression was defined as an increase of Expanded
Disability Status Scale score of at least 1·0 point for patients with a baseline score of
1·0 or more, or an increase of at least 1·5 points for patients with a baseline score of
0, confirmed after 12 weeks. For the rest, EDSS increase of ≥1 point if EDSS ≤5.5; 
EDSS increase of ≥0.5 point if EDSS > 5.5;  
(f) Includes adjusted MSFC z-score; also it may include values obtained at an early
termination time point if this occurred after 12 months.
(g) Includes time to sustained accumulation of disability, which is considered as
increase in 1 point in EDSS sustained for a minimum of 12 weeks (Confavreux et al.,
Lancet Neurol 2014, TOWER trial)
(h) No MRI activity includes: no new/enlarging lesions and no gadolinium-enhancing
lesions
(i) Includes relapses requiring hospitalization/IV steroids (Comi et al., NEJM 2012,
ALLEGRO study)
(j) Adjusting for baseline values of MSFC z-score, ANCOVA model
(k) Mean change reported, unless otherwise specified
40
(l) It includes ‘at least 1 major relapse’
(m) The authors also estimated the proportion of patients with: i) at least one MS-
related admission to hospital; ii) at least 1 MS-rekated steroid course
(n) The results shown refer to the comparative phase (0-12m) of the trial, where half
of the patients were receiving IFN beta-1a IM 30mcg/week and the other half IFN
beta-1a SC 44mcg tiw.
(o) p-value not specified
(p) this analysis refers to disability progression in both hands
(q) worsening in 9HPT is defined as deterioration greater or equal to 20%
(r) confirmed at 2 months
(s) mean number of relapses per patient during the trial/2 years (duration of trial)
(t) defined as 2-step increase (sustained for 3 months)
(u) in this context, this outcome measure (risk ratio or odds ratio) is equivalent to
hazard ratio in the survival model
(v) timing for CDP not specified. Assumed 3 months
(w) this study looked at disability progression at the end of FU, so it is possible that
just progression confirmed at just 3 months is also included here
(x) This refers to McDonald 2005 criteria
Abbreviations. BD: twice per day; CDP: confirmed disability progression; CI:
confidence interval; eod: every other day; FU: follow-up; GA: glatiramer acetate; HR:
hazard ratio; IA & AHSCT: immunoablation and autologous haemopoietic stem-cell
transplantation; IFN: interferon; IQR: interquartile range; MIU: million international
units; MSCT: mesenchymal stem cell transplantation; MSFC: Multiple Sclerosis
Functional Composite; MSIS-29: Multiple Sclerosis Impact Scale – 29 items; PO: per
oral; RFSS: Regional Functional System Score; SC: subcutaneous; SF-36: Short Form
36 Health Survey (SF-36); SNRS: Scripps Neurological Rating Scale; TDS: three times
per day; tiw: three times in a week; TSQM: Treatment Satisfaction Questionnaire for
Medication, with domains for Effectiveness, Side-Effects, Convenience and Global
Satisfaction
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study) 0.50 (0.37 to
0.69), p < 0.001;
IFN beta-1a
44mcg SC tiw vs.
placebo: HR =
0.60 (0.44 to
0.81), p = 0.001;
Mean annualised
hospitalisation





























































































































































SPMS (n=718) IFN beta-1b 8
million IU eod vs.
placebo: OR (95%
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SPMS (n=618) IFN beta-1a
22mcg SC tiw vs.
placebo: HR 0.88,
p = 0.305; IFN
beta-1a 44mcg SC
tiw vs. placebo:
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SPMS (n=371) IFN beta-1a SC
22mcg/week vs.
placebo: HR (95%
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PPMS (n=970) Fingolimod 0.5mg
PO/day vs.
placebo: HR (95%


























































































































































































































































SPMS (n=371) IFN beta-1a SC
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least 1 out of the
3:
-Increase in EDSS
(0.5 if EDSS≤5.5; 
1.0 if EDSS >6.0)
-Increase in ≥20% 
in 9HPT
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(a) ARR refers to mean ARR per each group; it includes confirmed relapse rate, which
includes rate of relapses with confirmed increase in EDSS (Voskuhl et al., Lancet
Neurol 2016) and also adjusted mean relapse rate (Vollmer et al., J Neurol 2014)
(b) No detailed figures provided
(c) Cognitive impairment was defined on the number of failed tests, as mild (one to
two tests failed) or moderate–severe (three or more tests failed)
(d) Defined as ≥7.5 points increase in MSIS-29 
(e) CDP: Confirmed disability progression was defined as an increase of Expanded
Disability Status Scale score of at least 1·0 point for patients with a baseline score of
1·0 or more, or an increase of at least 1·5 points for patients with a baseline score of
0, confirmed after 12 weeks. For the rest, EDSS increase of ≥1 point if EDSS ≤5.5; 
EDSS increase of ≥0.5 point if EDSS > 5.5;  
(f) Includes adjusted MSFC z-score; also it may include values obtained at an early
termination time point if this occurred after 12 months.
(g) Includes time to sustained accumulation of disability, which is considered as
increase in 1 point in EDSS sustained for a minimum of 12 weeks (Confavreux et al.,
Lancet Neurol 2014, TOWER trial)
(h) No MRI activity includes: no new/enlarging lesions and no gadolinium-enhancing
lesions
(i) Includes relapses requiring hospitalization/IV steroids (Comi et al., NEJM 2012,
ALLEGRO study)
(j) Adjusting for baseline values of MSFC z-score, ANCOVA model
(k) Mean change reported, unless otherwise specified
(l) It includes ‘at least 1 major relapse’
(m) The authors also estimated the proportion of patients with: i) at least one MS-
related admission to hospital; ii) at least 1 MS-rekated steroid course
(n) The results shown refer to the comparative phase (0-12m) of the trial, where half
of the patients were receiving IFN beta-1a IM 30mcg/week and the other half IFN
beta-1a SC 44mcg tiw.
(o) p-value not specified
(p) this analysis refers to disability progression in both hands
(q) worsening in 9HPT is defined as deterioration greater or equal to 20%
(r) confirmed at 2 months
(s) mean number of relapses per patient during the trial/2 years (duration of trial)
(t) defined as 2-step increase (sustained for 3 months)
(u) in this context, this outcome measure (risk ratio or odds ratio) is equivalent to
hazard ratio in the survival model
(v) timing for CDP not specified. Assumed 3 months
(w) this study looked at disability progression at the end of FU, so it is possible that
just progression confirmed at just 3 months is also included here
(x) This refers to McDonald 2005 criteria
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Abbreviations. BD: twice per day; CDP: confirmed disability progression; CI:
confidence interval; eod: every other day; FU: follow-up; GA: glatiramer acetate; HR:
hazard ratio; IA & AHSCT: immunoablation and autologous haemopoietic stem-cell
transplantation; IFN: interferon; IQR: interquartile range; MIU: million international
units; MSCT: mesenchymal stem cell transplantation; MSFC: Multiple Sclerosis
Functional Composite; MSIS-29: Multiple Sclerosis Impact Scale – 29 items; PO: per
oral; RFSS: Regional Functional System Score; SC: subcutaneous; SF-36: Short Form
36 Health Survey (SF-36); SNRS: Scripps Neurological Rating Scale; TDS: three times
per day; tiw: three times in a week; TSQM: Treatment Satisfaction Questionnaire for
Medication, with domains for Effectiveness, Side-Effects, Convenience and Global
Satisfaction
54
Table 4: Brain MRI outcome measures in phase III trials in relapsing-remitting MS
Brain MRI
Inclusion criteria: controlled phase III clinical trials
Exclusion criteria: incomplete data presentation (e.g. missing values); descriptive findings in absence
of any statistical analysis; secondary analyses of clinical trials and extension studies evaluating the





























lesion rate 0.5 vs. 2.0
(p=0.0026)
24 months









lesions 9.4 vs. 13.7
(p<0.003) after 9 months
9 months
Polman et al., New







number of lesions 1.1 vs.
5.8 after 1 year
(p<0.001), 0.7 vs. 4.4
after 2 years (p<0.001),








Interferon beta-1a 500μg 
vs. 250μg vs. Glatiramer 
acetate, number of
lesions 3.3 vs. 3.3 vs. 4.6
after 2 years (p=0.25;
p=0.0009; p=0.011)
24 months






vs. 40mg, number of






Polman et al., New







number of lesions 0.1 vs.
0.4 after 1 year
(p<0.001), 0.0 vs. 0.4
after 2 years (p<0.001),














Interferon beta-1a 44μg 
vs. 22μg vs. Placebo, 
percent difference
compared to Placebo -
67% and -78% (p<0.0001)
after 2 years; median
number of lesions per
patient per scan 0.5 vs. -
24 months
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0.75 vs. 2.25 (p=0.0003;
p<0.0001; p<0.0001) after
6 months; percent of
scans with lesions 25% vs.
50% vs. 75% (p=0.0002;
p<0.0001; p<0.0001) after
6 months; and percent of
patients without lesions
31% vs. 19% vs. 8%
(p=0.0009; p<0.0001;
p<0.0001) after 6 months
Jacobs et al., New
Eng J Med 2000
(CHAMPS study)
CIS (n=383) Interferon beta-1a 30μg 
vs. Placebo, number of
lesions 1.5 vs. 2.8 after 6
months (p=0.01), 2.1 vs.
4.0 after 12 months











Comi et al., Lancet
2001
(ETOMS study)
CIS (n=309) Interferon beta-1a 22μg 
vs. Placebo, median
number of lesions per
patient per scan 2.0 vs.










Interferon beta-1a 44μg 
vs. 30μg, number of 
lesions 0.9 vs. 1.4
(p<0.001), percent of
scans with lesions 27% vs.
44% (p<0.001), percent of
patients with no lesions








Polman et al., New







number of lesions 1.2 vs.
6.1 after 1 year
(p<0.001), 0.7 vs. 4.9
after 2 years (p<0.001),
and 1.9 vs. 11.0 overall
(p<0.001)
24 months
Rudick et al., New







lesions 0.9 vs. 5.4 after 2
years (p<0.001)
24 months





Interferon beta-1a 44 μg 
vs. Glatiramer acetate 20
mg, lesions per patient
per scan 0.67 vs. 0.82
after 96 weeks (p=0.18);
proportion of scans per
patient with lesions




with no lesions 40% vs.
37% after 96 weeks
(p=0.51)
Cohen et al., New






0.5mg vs. Interferon beta-
1a (30μg/week), number 
of lesions 1.5 (p<0.001)
and 1.7 (p=0.004), vs. 2.6
after 12 months; percent
of patients free of lesions
48.0% (p=0.37) and 54.8%
(p=0.01), vs. 45.7% after
12 months
12 months
Kappos et al., New
Eng J Med 2010;







number of lesions 1.1
(p<0.001) and 1.0
(p<0.011), vs. 3.6 after 6
months, 1.5 (p<0.001)
and 1.6 (p<0.011), vs. 5.5
after 12 months, 1.1
(p<0.001) and 0.9
(p<0.011), vs. 4.3
between 13 and 24
months, 2.5 (p<0.001)
and 2.5 (p<0.011), vs. 9.8
after 24 months; percent
of patients lesion-free
58.7% (p<0.001) and
57.4% (p<0.001) vs. 26.4%
after 12 months, 69.8%
(p<0.001) and 72.8%
(p<0.001) vs. 33.2%
between 12 and 24
months, and 51.9%
(p<0.001) and 50.5%
















27.6% after 96 weeks;
relative reduction 73.4%
(p<0.001) and 76.9%
(p<0.001) after 96 weeks
96 weeks
O'Connor et al., New
Eng J Med 2011;
Wolinsky et al., Mult
Scler 2013
(TEMSO study)
RMS (1088) Teriflunomide 14mg and
7mg vs. Placebo, mean
difference from Placebo -












(SIMCOMBIN study) Simvastatin 80 mg, mean
number of lesions 2.96 vs.
2.52 after 12 months (ns)






Interferon beta-1a 44 μg, 
proportion of patients
with lesions 48% vs. 58%
after 2 years (p=0.04)
24 months






Interferon beta-1a 44 μg, 
proportion of patients
with lesions 46% vs. 68%
after 2 years (p<0.0001)
24 months







lesions 5.03 vs. 7.14
(p<0.001) at 12 and 24
months
24 months







240mg BID or TID or
Glatiramer acetate vs.
Placebo, number of
lesions 5.1 (p<0.001), 4.7
(p<0.001), 8.0 (p<0.001),
vs. 17.4 after 2 years
24 months
Gold et al., New Eng
J Med 2012; Arnold





240mg BID and TID vs.
Placebo, number of
lesions 2.6 (p=0.01) and
4.4 (p=0.01) vs. 17.6 after
96 weeks; in a sub-cohort
of 540 patients, 1.1
(p<0.0001) and 1.6
(p<0.0001) vs. 5.2 after 6
months, 1.6 (p<0.0001)
and 2.6 (p<0.0001) vs.
10.3 after 1 year, and 2.6
(p<0.0001) and 4.4
(p<0.0001) vs. 17.0 after 2
years
24 months
Khan et al., Ann
Neurol 2013;





Glatiramer acetate 40 mg
vs. Placebo, cumulative
number of lesions 3.650











every 4 vs. 2 weeks vs.
Placebo, number of
lesions 4.6 vs. 2.2 vs. 5.8
(p<0.0001; p<0.0001;
p=0.023) after 24 weeks,
and 7.9 vs. 3.6 vs. 10.9
(p<0.0001; p<0.0001;










(FREEDOMS II study) number of lesions 1.6
(p<0.001) and 2.3
(p<0.001), vs. 8.9 after 24
months; percent of
patients free of lesions
63% (p<0.001) and 50%











number of lesions 0.76 vs.
0.69 after 2 years
(p=0.75); and number of
patients with new lesions
(0, 1-2, ≥3) 27/11/12 vs. 
21/18/8 after 2 years
(p=0.41)
24 months






beta-1a 30 μg vs. Placebo, 
cumulative number of
lesions 10.88 (p=0.078) or
6.37 (p<0.001) vs. 13.03
after 12 an 24 months
24 months
Kappos et al., New





number of lesions 2.14 vs.
3.81 (p<0.001) after 24
weeks; 4.3 vs. 9.4








240mg BID and TID vs.
Glatiramer Acetate vs.
Placebo, number of
lesions 3.1 (p<0.0001), 2.8
(p<0.0001), and 4.6
(p<0.0001) vs. 9.5 after 1
year, 2.0 (p<0.0001), 1.9
(p<0.0001), and 3.4
(p<0.0001) vs. 8.0
between 1 and 2 years,
and 5.1 (p<0.0001), 4.7
(p<0.0001), and 8.0
















volume change -6.2% vs.
10.9% after 1 year
(p<0.001), -0.9% vs.
16.5% after 2 years
(p<0.001), -9.3% vs. 15.0
after 3 years (p=0.002)
24 months





Interferon beta-1a 30μg 
vs. Placebo, median
percent volume change -
13.1% vs. -3.3% after 1
104 weeks
59
year (P=0.02), and -13.2%









Interferon beta-1a 44μg 
vs. 22μg vs. Placebo, 
median percent volume
change -4.2% vs. -1.5% vs.
4.0% (p=0.0246;
p=0.0001; p=0.0001) after
6 months, -4.5% vs. -3.5%
vs. 6.4% (p=0.3809;
p=0.0001; p=0.0001) after
12 months, -3.1% vs. -
1.4% vs. 10.8% (p=0.0974;
p=0.0001; p=0.0001) after















3.0mL vs. 4.7mL (p=0.006)
after 9 months
9 months
Polman et al., New









15703.2mm3 after 1 year
(p=0.016), 14722.0mm3
vs. 17853.1mm3 lesions










Interferon beta-1a 44 μg 
vs. Glatiramer acetate 20










Interferon beta-1a 500μg 
vs. 250μg vs. Glatiramer 
acetate, percent volume
change 22.0% vs. 19.0%




Cohen et al., New






0.5mg vs. Interferon beta-
1a (30μg/week), percent 
volume change 6.7%
(p=0.48) and 9.9%
(p=0.63), vs. 10.4% after
12 months
12 months
Kappos et al., New RRMS Fingolimod 1.25mg and 24 months
60
Eng J Med 2010;
Radue et al., Arch
Neurol 2012
(FREEDOMS study)
(n=1272) 0.5mg vs. Placebo,
percent volume change
2.7% (p<0.001) and 3.4%
(p<0.001), vs. 18.7% after
12 months, 1.6%
(p<0.001) and 10.6%











vs. 0.095mL after 12
months (p=0.612)
12 months
O'Connor et al., New
Eng J Med 2011;
Wolinsky et al., Mult
Scler 2013
(TEMSO study)
RMS (1088) Teriflunomide 14mg and
7mg vs. Placebo, volume
change 0.39mL
(p<0.0001) and 0.81mL















(p<0.001) after 96 weeks
96 weeks






Interferon beta-1a 44 μg, 
median percent volume
change -9.3% vs. -6.5%
after 2 years (p=0.31)
24 months






Interferon beta-1a 44 μg, 
median percent volume
change -1.27% vs. -1.23%
after 2 years (p=0.14)
24 months
Gold et al., New Eng
J Med 2012; Arnold





240mg BID and TID vs.
Placebo, in a sub-cohort
of 540 patients, median
percent volume change -
3.5% (p<0.001) and -1.7%
(p<0.01) vs. 1.6% after 6
months, -5.8% (p<0.0001)
and -3.7% (p<0.0001) vs.
6.5% after 1 year, and -
6.2% (p<0.0001) and -
1.9% (p<0.0001) vs. 20.1%
after 2 years
24 months






SC/week + GA 20mg
SC/day vs IFN beta-1a
30mcg SC/week vs GA
20mg SC/day: volume















and 13.74% (p<0.001), vs.










every 4 and 2 weeks vs.
Placebo, volume change
0.14cm3 (p=0.0006) and -
0.22cm3 (p<0.0001) vs.
0.34cm3 after 24 weeks,
and 0.06cm3 (p<0.0001)
and -0.26cm3 (p<0.0001)
vs. 0.77cm3 after 48
weeks
24 months
Kappos et al., New






change -1.4% vs. 3.4%
(p=0.02) after 24 weeks;
0.2% vs. 8.6% (p<0.001)
after 96 weeks; volume of
new or newly enlarged T2
lesions 217.0mm3 vs.
463.1mm3 (p<0.001) after
















(p<0.0001) vs. 4.8% after
1 year, and -7.4%
(p<0.0001), -1.5%
(p<0.0001), and -6.3%




















percentage of scans with
lesions 5.9% vs. 29.4%
after 3 years (p=0.0062);
median number of lesions
per year 0.5 vs. 3.0
(p=0.0089)
24 months





Interferon beta-1a 30μg 
vs. Placebo, number of
lesions 1.04 vs. 1.59 after
1 year (p=0.02), and 0.80




lesions 29.9% vs. 42.3%
after 1 year (p=0.05)










lesions 36.8 vs. 26.0
(p=0.003) after 9 months;
mean number of lesions
per patient 2.9 vs. 4.1
(p<0.005) after 9 months;
total number of new
lesions 17.4 vs. 26
(p<0.003) after 9 months;
mean percent of scans
without lesions 28.7% vs.
35.8% (p=0.04) after 9
months
9 months
Polman et al., New







number of lesions 0.1 vs.
1.3 after 1 year (p<0.001),
0.1 vs. 1.2 after 2 years
(p<0.001), and 0.2 vs. 2.4
overall (p<0.001)
24 months
Rudick et al., New







lesions 0.1 vs. 0.9 after 2
years (p<0.001)
24 months





Interferon beta-1a 44 μg 
vs. Glatiramer acetate 20
mg, lesions per patient
per scan 0.24 vs. 0.41
after 96 weeks
(p=0.0002); scans per
patient with lesions 9.8%








Interferon beta-1a 500μg 
vs. 250μg vs. Glatiramer 
acetate, number of
lesions 1.0 vs. 0.9 vs. 1.2
after 2 years (p=0.80;
p=0.07; p=0.12)
24 months
Cohen et al., New






0.5mg vs. Interferon beta-
1a (30μg/week), number 
of lesions 0.14 (p<0.001)
and 0.23 (p<0.001), vs.
0.51 after 12 months
12 months
Kappos et al., New
Eng J Med 2010;







number of lesions 0.3
(p<0.001) and 0.2




and 0.2 (p<0.011), vs. 1.1
after 12 months, 0.2
(p<0.001) and 0.2
(p<0.011), vs. 1.1 after 24
months






vs. 40mg, number of















(p<0.001) after 96 weeks
96 weeks
O'Connor et al., New
Eng J Med 2011;
Wolinsky et al., Mult
Scler 2013
(TEMSO study)
RMS (1088) Teriflunomide 14mg and
7mg vs. Placebo, lesions




1.33 after 108 weeks
108 weeks






Interferon beta-1a 44 μg, 
patients with lesions 7%
vs. 19% (p<0.0001)
24 months






Interferon beta-1a 44 μg, 
patients with lesions 9%
vs. 23% (p<0.0001)
24 months
Comi et al., NEJM








lesions 1.33 vs. 2.12
(p<0.001) at 12 and 24
months
24 months







240mg BID or TID or
Glatiramer acetate vs.
Placebo, number of
lesions 0.5 (p<0.001), 0.4
(p<0.001), 0.7 (p<0.001),
vs. 2.0 after 2 years
24 months
Gold et al., New Eng
J Med 2012; Arnold





240mg BID and TID vs.
Placebo, number of
lesions 0.1 (p<0.001), 0,5
(p<0.001), vs. 1.8 after 96
weeks; in a sub-cohort of
540 patients, 0.1
(p<0.0001) and 0.3
(p<0.0001) vs. 1.5 after 6
months, 0.1 (p<0.0001)
and 0.4 (p<0.0001) vs. 1.4
after 1 year, and 0.1
(p<0.0001) and 0.5




Khan et al., Ann
Neurol 2013;





Glatiramer acetate 40 mg
vs. Placebo, cumulative
number of lesions 0.905











every 4 vs. 2 weeks vs.
Placebo, number of
lesions 1.2 vs. 0.3 vs. 1.6
(p<0.0001; p<0.0001;
p=0.099) after 24 weeks,
and 0.9 vs. 0.2 vs. 1.4
(p<0.0001; p<0.0001;









number of lesions 0.2
(p<0.001) and 0.4










vs. Interferon, number of
lesions 0.2 vs. 0.4 after 2
years (p=0.52); and
number of patients with
lesions (0, 1-2, ≥3) 41/8/0 
vs. 43/1/3 after 2 years
(p=0.39)
24 months






beta-1a 30 μg vs. Placebo, 
cumulative number of
lesions 1.84 (p=0.069) or
0.90 (p<0.001) vs. 2.34
after 12 an 24 months
24 months







generic or brand version
vs. Placebo, number of
lesions 0.42 (p<0.001), or
0.38 (p<0.001), vs. 0.82
during months 7 through
9; ratio of generic drug to
brand drug of 1.095
9 months
Kappos et al., New





number of lesions 0.5 vs.









240mg BID and TID vs.
Glatiramer Acetate vs.
Placebo, number of
lesions 0.5 (p<0.0001), 0.5
(p<0.0001), and 1.6
(p<0.05) vs. 1.7 after 24
weeks, 0.4 (p<0.0001),
0.4 (p<0.0001), and 0.7
24 months
65
(p<0.0001) vs. 2.2 after 1
year, and 0.5 (p<0.0001),
0.4 (p<0.001), and 0.8












Interferon beta-1a 44 μg 
vs. Glatiramer acetate 20
mg, patients with no
lesions 81% vs. 67% after
96 weeks (p=0.0005)
96 weeks
Kappos et al., New
Eng J Med 2010;







percent of patients free
of lesions -87.8%
(p<0.001) and 88.3
(p<0.001), vs. 64.3% after
12 months, 89.8%
(p<0.001) and 89.7%
(p<0.001), vs. 65.1% after
24 months
24 months
Cohen et al., New






0.5mg vs. Interferon beta-
1a (30μg/week), percent 
of patients free of lesions
91.2% (p<0.001) and
90.1% (p<0.001), vs.
80.8% after 12 months
12 months
O'Connor et al., New
Eng J Med 2011;
Wolinsky et al., Mult
Scler 2013
(TEMSO study)
RMS (1088) Teriflunomide 14mg and
7mg vs. Placebo, percent
of patients free of lesions
64.1% (p<0.001) and













patients free of lesions
87.2% (p<0.001) and
91.4% (p<0.001), vs.









percent of patients free
of lesions 96% (p<0.001)
and 87% (p<0.001), vs.
65% after 24 months
24 months







40 mg, percent of
patients with lesions 8%












Interferon beta-1a 30μg 
vs. Placebo, lesion volume
70.0mm3 vs. 96.5mm3




after 2 years (p=0.03)








Placebo, volume change -
245.3μL vs. -105.1μL 
(p=0.01) after 9 months
9 months
Polman et al., New







lesion volume of 21mm3
vs. 207mm3 after 1 year
(p<0.001), 32mm3 vs.
192mm3 after 2 years
(p<0.001); volume change
-343mm3 vs. -126mm3
after 1 year (p<0.001),
and -332mm3 vs. -
141mm3 after 2 years
(p<0.001)
24 months





Interferon beta-1a 44μg 
vs. Glatiramer acetate 20
mg, volume change -
164.3mm3 vs. -162.6mm3







Interferon beta-1a 500μg 
vs. 250μg vs. Glatiramer 
acetate, cumulative
volume 0.11cm3 vs.
0.12cm3 vs. 0.14cm3 after
2 years (p=0.87; p=0.028;
p=0.017)
24 months
Cohen et al., New






0.5mg vs. Interferon beta-






Gold et al., New Eng
J Med 2012; Arnold





240mg BID and TID vs.
Placebo, in a sub-cohort
of 540 patients, median
volume change -
203.2mm3 (p<0.01) and -
118.7mm3 (p<0.05) vs. -
1.8mm3 after 6 months, -
160.9mm3 (p<0.01) and -
110.2mm3 (p<0.01) vs. -
12.6mm3 after 1 year, and
-152.7mm3 (p<0.0001)
and -57.8mm3 (p<0.0001)

























141.8mm3 after 2 years
T1 lesions Number of
new T1
lesions
Polman et al., New







number of lesions 0.6 vs.
2.3 after 1 year (p<0.001),
0.4 vs. 2.3 lesions after 2
years (p<0.001), and 1.1
vs. 4.6 overall (p<0.001)
24 months





Interferon beta-1a 44 μg 
vs. Glatiramer acetate 20
mg, lesions per patient
per scan 0.23 vs. 0.24
after 96 weeks (p=0.15);
scans per patient with
lesions 10.5% vs. 12.4%
after 96 weeks (p=0.12);
patients with no lesions
75% vs. 70% after 96
weeks (p=0.29)
96 weeks
O'Connor et al., New
Eng J Med 2011;
Wolinsky et al., Mult
Scler 2013
(TEMSO study)
RMS (1088) Teriflunomide 14mg and
7mg vs. Placebo, mean
difference from Placebo -




Comi et al., New Eng
J Med 2012; Filippi








lesions 1.61 vs. 2.23
(p=0.004) after 24 months
24 months







240mg BID or TID or
Glatiramer acetate vs.
Placebo, number of
lesions 3.0 (p<0.001), 2.4
(p<0.001), 4.1 (p=0.002),










every 4 vs. every 2 weeks,
vs. Placebo, number of
lesions 2.0 vs. 1.2 vs. 2.1
(p<0.0001; p<0.0001;
p=0.23) after 24 weeks,




p=0.082) after 48 weeks
Kappos et al., New





number of lesions 1.22 vs.
1.94 (p<0.001) after 24
weeks; 2.13 vs. 4.43






Polman et al., New







number of lesions 0.6 vs.
1.9 after 1 year
(p<0.001), 0.4 vs. 1.9
after 2 years (p<0.001),














and 8.2% (p<0.001) after
96 weeks
96 weeks
Gold et al., New Eng
J Med 2012; Arnold





240mg BID and TID vs.
Placebo, in a sub-cohort
of 540 patients, number
of lesions 0.8 (p<0.0001)
and 1.0 (p<0.001) vs. 1.9
after 6 months, 1.1
(p<0.0001) and 1.4
(p<0.0001) vs. 3.5 after 1
year, and 1.5 (p<0.0001)
and 2.1 (p<0.0001) vs. 5.6
after 2 years
24 months
Khan et al., Ann
Neurol 2013;






vs. Placebo, number of
lesions 0.31 vs. 0.45
(p=0.0258) between 6
and 12 months;
proportion of new active
lesions converting to T1










240mg BID and TID vs.
Glatiramer Acetate vs.
Placebo, number of
lesions 2.2 (p<0.001), 1.5
(p<0.0001), and 2.6
(p<0.05) vs. 3.7 after 1
year, 1.0 (p<0.0001), 0.9
(p<0.0001), and 1.5
(p<0.001) vs. 3.3 between
1 and 2 years, and 3.0
(p<0.0001), 2.4
(p<0.0001), and 4.1















0.8mL vs. 1.3mL (p=0.14)
after 9 months
9 months
Polman et al., New







volume after 1 (p=0.004)
and 2 years (p<0.001);
volume change of -
1508mm3 vs. 548mm3
overall (p<0.001); percent
change -23.5% vs. -1.5%
overall (p<0.001)
24 months





Interferon beta-1a 44 μg 
vs. Glatiramer acetate 20
mg, volume change -
667.0 mm3 vs. -377.3mm3







Interferon beta-1a 500μg 
vs. 250μg vs. Glatiramer 
acetate, percent volume
change 36.0% vs. 23.1%
vs. 40.6% after 2 years
(p=0.18; p=0.54; p=0.68)
24 months
Cohen et al., New






0.5mg vs. Interferon beta-
1a (30μg/week), percent 
volume change 34.7%
(p=0.09) and 24.1%
(p=0.17), vs. 15.0% after
12 months
12 months
Kappos et al., New
Eng J Med 2010;










after 24 months; percent
volume change 12.2%
(p=0.02) and 8.8%
(p=0.01), vs. 50.7% after
24 months
24 months
O'Connor et al., New
Eng J Med 2011;






7mg vs. Placebo, volume
change 0.33mL (p=0.02)
and 0.50mL (p=0.19) vs.











vs. 0.019mL after 12
months (p=0.547)
12 months
Gold et al., New Eng
J Med 2012; Arnold





240mg BID and TID vs.
Placebo, in a sub-cohort




1.5% (ns) and 2.5% (ns)
vs. 4.3% after 6 months,
5.4% (p<0.05) and 4.7%
(ns) vs. 11.6% after 1
year, and 8.4% (p<0.0001)
and 12.7% (p<0.01) vs.
26.9% after 2 years
Calabresi et al.,
Lancet Neurol 2014;






every 4 and 2 weeks vs.
Placebo, volume change
0.31cm3 (p<0.0001) and -
0.18cm3 (p<0.0001) vs.
0.29cm3 after 24 weeks,
and 0.57cm3 (p=0.018)
and -0.32cm3 (p<0.0001)










percent volume change -
4.69% (p=0.205) and
12.64% (p=0.372), vs.
26.42% after 24 months
24 months
Kappos et al., New






10.5% vs. 14.1% (p<0.001)
after 24 weeks; 22.8% vs.















(p=0.2741) vs. 7.9% after
1 year, and 10.7%
(p<0.001), 8.5% (p<0.01),
and 8.6% (p<0.01) vs.





Comi et al., NEJM







Number of PBH from Gd+
lesions: 1.0 vs. 2.1
(p=0.001); Number of
PBH from new T2 lesions:
0.87 vs. 1.67 (p=0.009);
Number of PBH from Gd+
lesions and new T2
lesions: 1.20 vs. 2.34
(p<0.001); Proportion of
Gd+ lesions converting to
PBH: 21% vs. 29%
(p=0.117); Proportion of
new T2 lesions converting
24 months
71
to PBH: 23% vs. 26%
(p=0.572); Proportion of
Gd+ lesions and new T2
lesions converting to PBH:
23% vs. 28% (p=0.260);
T1/T2 lesion
volume ratio
Polman et al., New







ratio 0.270 vs. 0.311 after
2 years (p=0.002
adjusting for the baseline
ratio); changes in the
ratio -0.058 vs. vs. -0.03













Interferon beta-1a 44 μg 
vs. Glatiramer acetate 20
mg, lesions per patient
per scan 0.91 vs. 1.22
after 96 weeks (p=0.010);
scans per patient with
lesions 26.4% vs. 32.3%
after 96 weeks (p=0.009);
patients with no lesions
38% vs. 31% after 96
weeks (p=0.125)
96 weeks
Kappos et al., New
Eng J Med 2010;














between 12 and 24
months, and 52.0%
(p<0.001) and 50.7%













patients with MRI lesion
activity-free 60.0%
(p<0.001) and 61.2%
(p<0.001), vs. 25.5% after
96 weeks; relative
reduction: 0.43 (p<0.001)
and 0.38 (p<0.001) vs.
1.72 after 96 weeks
96 weeks
O'Connor et al., New
Eng J Med 2011;
Wolinsky et al., Mult
Scler 2013
(TEMSO study)
RMS (1088) Teriflunomide 14mg and









Comi et al., Lancet
Neurol 2012
(REFLEX study)
CIS (n=517) Interferon beta-1a three
times a week vs. once a
week vs. Placebo, number
of lesions per patient per
scan 0.60 vs. 1.23 vs. 2.70
(p<0.0001; p<0.0001;
p=0.0015) after 2 years
108 weeks






SC/week + GA 20mg
SC/day vs IFN beta-1a
30mcg SC/week vs GA
20mg SC/day: percent of
patients free of lesions












every 4 vs. 2 weeks vs.
Placebo, percent of
patients without MRI
activity 24.9% vs. 40.9%
vs. 19.1% (p<0.0001;
p<0.0001; p=0.0318) after
48 weeks, 34.2% vs.
46.4% vs. 26.2%
(p=0.0002; p<0.0001;
p=0.0078) after 24 weeks,
and 39.8% vs. 65.4% vs.
31.5% (p<0.0001;
p<0.0001; p=0.0080)
between 24 and 48
weeks; mean number of
lesions 7.3 (p<0.001), and










percent of patient free of
MRI activity 63%
(p<0.001) and 50%












number of lesions 0.78 vs.
















RMS (n=715) Linomide vs. Placebo, Z4
score -0.05 vs. 0.13











O'Connor et al., New
Eng J Med 2011;
Wolinsky et al., Mult
Scler 2013
(TEMSO study)
RMS (1088) Teriflunomide 14mg and









Polman et al., New







percent volume change -
0.56% vs. -0.40% after 1
year (p=0.002), -0.43% vs.
-0.24% after 2 years
(p=0.004), and -0.80 vs. -
0.82 overall (ns)
24 months





Interferon beta-1a 44 μg 
vs. Glatiramer acetate 20
mg, percent volume
change -1.240% vs. -








Interferon beta-1a 500μg 
vs. 250μg vs. Glatiramer 
acetate, percent volume
change -0.64% vs. -0.65%
vs. -0.61% after 2 years
(p=0.74; p=0.33; p=0.46)
24 months
Cohen et al., New






0.5mg vs. Interferon beta-






Kappos et al., New
Eng J Med 2010;











(39.2%) (p=0.003) vs. -
0.34% after 6 months, -
0.44% (22.7%) (p=0.03)
and -0.50% (32.3%)
(p=0.001) vs. -0.65% after
12 months, -0.42%
(36.8%) (p=0.002) and -
0.37% (44.7%) (p<0.001)
vs. -0.67% between 12
and 24 months, -0.89%
(35.5%) (p<0.001) and -
0.84% (32.2%) (p<0.001)
vs. -1.31% after 24
months
24 months





vs. 40mg, percent volume
12 months
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(FORTE study) change -0.58% vs. -0.53%











after 12 months (p=0.370)
12 months






Interferon beta-1a 44 μg, 
median percent volume
change -0.867% vs. -
1.488% after 2 years
(p<0.0001)
24 months






Interferon beta-1a 44 μg, 
median percent volume
change -0.615% vs. -
0.810% after 2 years
(p=0.01)
24 months






percent volume change -
0.87% vs. -1.30%
(p<0.001) after 24 months
24 months
Gold et al., New Eng
J Med 2012; Arnold





240mg BID and TID vs.
Placebo, in a sub-cohort
of 540 patients, median
percent volume change -
0.64% (p<0.05) and -
0.77% (ns) vs. -0.81%
after 6 months, -0.46%
(p<0.05) and -0.55% (ns)
vs. -0.66% between 6
months and 2 years
24 months
Khan et al., Ann
Neurol 2013





Glatiramer acetate 40 mg
vs. Placebo, percent
volume change -0.706%

























percent volume change -
0.128% (p<0.001) and -
0.228% (p=0.012), vs. -
0.375% after 6 months; -
0.354% (p<0.001) and -
0.377% (p=0.0004), vs. -
0.629% after 12 months; -
24 months
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0.285% (p<0.001) and -
0.486% (p=0.013), vs. -
0.678% after 24 months






beta-1a 30 μg vs. Placebo, 
percent volume change -
0.75% (p<0.001) or -



















between 1 and 2 years,
and -0.660% (p=0.0645), -
0.750% (p=0.2636), and -
0.960% (p=0.8802) vs. -
0.945% after 2 years
24 months







40 mg, percent volume
change -0.367% vs. -
0.302% after 1 year (ns), -
0.382% vs. -0.545% after
2 years (ns); percent
annualized volume
change -0.380% vs. -
0.316% (p=0.920)
24 months
Grey matter O'Connor et al., New
Eng J Med 2011;
Wolinsky et al., MSJ
2013
(TEMSO study)
RMS (1088) Teriflunomide 14mg and














change -0.3% vs. -0.8%
(p=0.004) after 12
months, -0.7% vs. -0.6%
(p=0.664) between 12
and 24 months, and -0.9%
vs. -1.2% (p=0.372) after
24 months
24 months






SC/week + GA 20mg
SC/day vs IFN beta-1a




volume change -2.60% vs.
-2.99% vs. -5.16% (ns; ns)
after 36 months
White matter O'Connor et al., New
Eng J Med 2011;





















change -0.0% vs. -0.4%
(p=0.004) after 12
months, -0.2% vs. -0.2%
(p=0.857) between 12
and 24 months, and -0.3%
vs. -0.5% (p=0.327) after
24 months
24 months






SC/week + GA 20mg
SC/day vs IFN beta-1a
30mcg SC/week vs GA
20mg SC/day: volume
change  −1.73mL (SD 
22.63) vs.  −0.71mL 










SC/week + GA 20mg
SC/day vs IFN beta-1a
30mcg SC/week vs GA
20mg SC/day: percent
volume change 0.60% vs.
0.51% vs. 0.57% (ns; ns)
after 36 months
36 months








change -0.6% vs. -1.0%
(p=0.005) after 12
months, -0.7% vs. -0.9%
(p=0.233) between 12
and 24 months, and -1.3%
vs. -1.8% (p=0.003)
24 months
MTR Whole brain Gold et al., NEJM







Dimethyl fumarate BID vs.
TID vs. placebo: percent
change:
BID: 0.129%, p (vs.
placebo) 0.0027;















every 4 vs. 2 weeks vs.
Placebo, percent change
-0.432% (p=0.6873), and -
0.129% (p=0.0438), vs. -
0.382% after 1 year
24 months







signal change 0.31 vs. -
0.09 (p=0.013) after 12
months, -0.08 vs. -0.18
(p=0.642) between 12
and 24 months, and 0.23









240mg BID and TID vs.
Glatiramer Acetate vs.
Placebo, percent change:
-0.167 (ns), -0.008 (ns),
and 0.010 (ns) vs. -0.419
after 2 years
24 months







signal change 0.32 vs. -
0.09 (p=0.013) after 12
months, -0.05 vs. -0.18
(p=0.486) between 12
and 24 months, and 0.27
vs. -0.27 (p=0.011) after
24 months
24 months







signal change 0.30 vs. -
0.11 (p=0.014) after 12
months, -0.16 vs. -0.22
(p=0.787) between 12
and 24 months, and 0.14
vs. -0.33 (p=0.034) after
24 months
24 months







signal change 0.39 vs.
0.02 (p=0.239) after 12
months, 0.07 vs. -0.08
(p=0.651) between 12
and 24 months, and 0.46












signal change 0.047 vs. -
0.176 (p=0.179) after 24
months
24 months
Abbreviations: Gd: gadolinium; MTR: magnetisation transfer ratio; NAA/Cr: N-acetyl aspartate-
creatine ratio; RRMS: relapsing-remitting MS.
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Table 5: Brain MRI outcome measures in phase III trials in CIS
Brain MRI
Inclusion criteria: controlled phase III clinical trials
Exclusion criteria: incomplete data presentation (e.g. missing values); descriptive findings in absence
of any statistical analysis; secondary analyses of clinical trials and extension studies evaluating the




























CIS (n=487) Interferon beta-1b vs.
Placebo, cumulative
number of lesions 2.9 vs.
4.4 up to the conversion to
MS (p<0.0001), 2.2 vs. 4.6







CIS (n=481) Glatiramer Acetate vs.
Placebo, number of lesions














CIS (n=383) Interferon beta-1a 30μg vs. 
Placebo, number of lesions
1.5 vs. 2.8 after 6 months
(p=0.01), 2.1 vs. 4.0 after
12 months (p<0.001), 2.1


















CIS (n=309) Interferon beta-1a 22μg vs. 
Placebo, median number
of lesions per patient per









CIS (n=616) Cladribine 5.25 mg/Kg or
3.5 mg/Kg, vs. Placebo,
median cumulative number
of lesions 0.0 or 0.0 vs. 2.0








CIS (n=618) Teriflunomide 14mg vs.

















CIS (n=383) Interferon beta-1a 30μg vs. 
Placebo, median volume
change -123mm3 vs.
40mm3 after 6 months
(p<0.001), 102mm3 vs.
214mm3 after 12 months
(p=0.004), 28mm3 vs.
















CIS (n=309) Interferon beta-1a 22μg vs. 
Placebo, median volume
change -487mm3 vs. -
299mm3 after 2 years
(p=0.002); median percent
volume change -13.0% vs.













CIS (n=487) Interferon beta-1b vs.
Placebo, volume change -
888.5mm3 vs. -431.6mm3
up to the conversion to MS
(p<0.05), -1.0cm3 vs. -









CIS (n=618) Teriflunomide 14mg vs.



















CIS (n=383) Interferon beta-1a 30μg vs. 
Placebo, number of lesions
0.9 vs. 1.5 after 6 months
(p=0.03), 0.7 vs. 1.6 after
12 months (p=0.02), 0.4 vs.
















CIS (n=309) Interferon beta-1a 22μg vs. 
Placebo, median number
of lesions per patient per










CIS (n=487) Interferon beta-1b vs.
Placebo, cumulative
number of lesions 1.9 vs.
4.3 up to conversion to MS
(p<0.0001), 2.2 vs. 4.6 after
2 years (p<0.001); new













CIS (n=616) Cladribine 5.25 mg/Kg or
3.5 mg/Kg, vs. Placebo,
median cumulative number
of lesions 0.0 or 0.0 vs. 2.0








CIS (n=618) Teriflunomide 14mg vs.
7mg vs. Placebo, number
of lesions per scan 0.395
(p=0.0008) vs. 0.749





















up to conversion to MS
(p<0.0001), 0.2cm3 vs.
0.5cm3 after 2 years
(p<0.001); volume of
lesions per scan 0.1cm3 vs.









CIS (n=618) Teriflunomide 14mg vs.
7mg vs. Placebo, volume
change 0.034mL(p<0.0001)
vs. 0.058mL (p=0.0077) vs.
0.079mL after 108 weeks
108 weeks












CIS (n=487) Interferon beta-1b vs.
Placebo, cumulative
number of lesions 0.2 vs.








CIS (n=481) Glatiramer Acetate vs.
Placebo, cumulative
number of lesions 1.7 vs.











CIS (n=618) Teriflunomide 14mg vs.








CIS (n=487) Interferon beta-1b vs.











of lesions -0.0cm3 vs. -












CIS (n=309) Interferon beta-1a 22μg vs. 
Placebo, proportion of
patients without lesions













CIS (n=487) Interferon beta-1b vs.
Placebo, cumulative
number of lesions 3.7 vs.
8.5 up to the conversion to
MS (p<0.001), 5.7 vs. 10.3








CIS (n=517) Interferon beta-1a three
times a week vs. once a
week vs. Placebo, number
of lesions per patient per
scan 0.60 vs. 1.23 vs. 2.70
(p<0.0001; p<0.0001;








CIS (n=616) Cladribine 5.25 mg/Kg or
3.5 mg/Kg, vs. Placebo,
median cumulative number
of lesions 1.0 or 1.0 vs. 4.0










CIS (n=481) Glatiramer Acetate vs.
Placebo, percent volume









CIS (n=618) Teriflunomide 14mg vs.






Abbreviations: Gd: gadolinium; CIS: clinically isolated syndrome.
82
Table 6: Brain MRI outcome measures in phase III trials in progressive MS
Brain MRI
Inclusion criteria: controlled phase III clinical trials
Exclusion criteria: incomplete data presentation (e.g. missing values); descriptive findings in absence
of any statistical analysis; secondary analyses of clinical trials and extension studies evaluating the


































































2.67 vs. 3.44 after
1 year (ns), 2.45





















































































































































SPMS (n=939) Interferon beta-
























58% after 3 years
(p=0.1344)
36 months
Hawker et al., Ann
Neurol 2009
(OLYMPUS study)


















































1.62 vs. 1.47 after
1 year (ns), 1.14






after 1 year (ns),
32.1% vs. 28.3%










SPMS (n=939) Interferon beta-




















-47% after 2 years
(p=0.0702), and -






SPMS (n=612) MBP8298 vs.
Placebo, lesion
change among
DR2+ or DR4+ 1.1





























































































after 1 year (ns),
0.123 vs. 0.136





































Hawker et al., Ann
Neurol 2009
(OLYMPUS study)

















after 1 year (ns), -
0.11% vs. -0.06%





SPMS (n=612) MBP8298 vs.
Placebo, percent
change among








































x2) /24 weeks IV
vs. placebo: rate
of brain volume
loss: -0.9% vs. -
1.1% (p=0.0206)
120 weeks
Abbreviations: Gd: gadolinium; PPMS: primary progressive multiple sclerosis; SPMS: secondary
progressive multiple sclerosis.
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Interferon beta-1b (250μg on 
alternate days) vs. Placebo, percent
change in cord area -1.6% vs. -1.3%
after 12 months (ns), -0.9% vs. -





PPMS (n=50) Interferon beta-1a (30μg vs. 60μg 
per week) vs. Placebo, percent
change in cord area -0.5% vs. -1.0%
vs. 0.3% after 12 months (ns), -
3.7% vs. 1.5% vs. -1.3% after 24
months (ns)
24 months







Interferon beta-1a (44μg three 
times per week), percent change in
cord area -1.0% vs. -1.7% after 6
months (ns), -1.5% vs. -2.8% after
12 months (ns), -1.8% vs. -2.9%
after 18 months (ns), -4.5% vs. -













SPMS (n=120) Lamotrigine vs. Placebo, percent
change in cord area -1.60% vs. -





PPMS (n=16) Placebo for 12 months vs. Riluzole
for following 12 months (2x50mg
per day), percent change in cord







PPMS (n=823) Fingolimod vs. Placebo, % change
from baseline: percent change in
cord area -2.04% vs. -2.44% after
24 months (ns)
24 months
Abbreviations: ns: not significant; PPMS: primary progressive multiple sclerosis; RRMS: relapsing-
remitting multiple sclerosis; SPMS: secondary progressive multiple sclerosis
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Vitamin D (20400 IU every
other day) vs. Vitamin D (400









(crossover), percent change -
1.89% vs. 1.45% after 5 weeks








Fluoxetine (40mg per day) vs.
Placebo, ongoing
108 weeks
Llufriu et al. PloS
ONE 2014, phase
II
RRMS (n=9) Autologous Mesenchymal
Stem Cells vs. Placebo,
change in thickness OD -
0.2μm vs. 0.0μm (ns) and OS -
0.33μm vs. -0.22μm (ns) after 
6, and OD -0.02μm vs. -
0.02μm (ns) and OS -0.4μm 
vs. 0.0μm (ns) after 12 
months
12 months
Diem et al. BMJ
Open 2015,
phase II
Acute ON in CIS
(n=100,
expected)
Erythropoietin (33000 IU per
day for 3 consecutive days)
vs. Placebo, ongoing
6 months
McKee et al. BMJ
Open 2015,
phase II















Salari et al. J Res
Med Sci 2015,
phase II
Acute ON in CIS
(n=52)
Vitamin D (50000 IU per
week) vs. Placebo, change in
thickness -19.9μm vs. -
17.6μm (ns) 
6 months
Sergott et al. J
Neurol Sci 2015,
phase II
Acute ON in CIS
(n=34)
Atacicept vs. Placebo, change






Acute ON in CIS
and RRMS
(n=86)
Phenytoin vs. Placebo, 30%
reduction in thickness in the






McKee et al. BMJ
Open 2015,
phase II











Vitamin D (20400 IU every
other day) vs. Vitamin D (400

















Fluoxetine (40mg per day) vs.
Placebo, ongoing
108 weeks
Llufriu et al. PloS
ONE 2014, phase
II
RRMS (n=9) Autologous Mesenchymal
Stem Cells vs. Placebo,
volume change OD -0.02mm3
vs. 0.0mm3 (ns) and OS -
0.02mm3 vs. -0.02mm3 (ns)
after 6, and OD -0.02mm3 vs.
0.0mm3 (ns) and OS -0.01mm3
vs. 0.01mm3 (ns) after 12
months
12 months
Diem et al. BMJ
Open 2015,
phase II
Acute ON in CIS
(n=100,
expected)
Erythropoietin (33000 IU per
day for 3 consecutive days)
vs. Placebo, ongoing
6 months
McKee et al. BMJ
Open 2015,
phase II

















Acute ON in CIS
and RRMS
(n=86)
Phenytoin vs. Placebo, 34%
volume reduction in the





McKee et al. BMJ
Open 2015,
phase II






Salari et al. J Res
Med Sci 2015,
phase II
Acute ON in CIS
(n=52)
Vitamin D (50000 IU per
week) vs. Placebo, thickness
change -0.8μm vs. -3.1μm (ns)
6 months
Abbreviations: CIS: clinically isolated syndrome; ns: not significant; ON: optic neuritis; PPMS: primary
progressive multiple sclerosis; RRMS: relapsing-remitting multiple sclerosis; SPMS: secondary
progressive multiple sclerosis.




